Tag Archives: FDI

Guangdong’s International Medical Services Pilot: Foreign-Patient Growth, Wholly Foreign-Owned Hospitals and What It Means for Healthcare Investors

  • At the 17 August 2026 press conference marking China’s Doctors’ Day, Guangdong’s health commission reported that visits by foreign patients at the 25 pilot international-medical-service hospitals grew 95.6% year on year since the pilot launched in February 2026.
    2026 年 8 月 17 日广东医师节新闻发布会上,省卫健委通报:自 2026 年 2 月国际医疗服务试点启动以来,25 家试点医院外籍人士就医人次同比增长 95.6%。
  • Hong Kong University-Shenzhen Hospital, one of the 25 pilots, has treated patients from 129 countries and regions and served 720,000 foreign patients in the past three years; in 2026 its international medical centre business grew 17.8% year on year from January to July.
    试点之一的香港大学深圳医院已接诊来自 129 个国家和地区的患者,近三年服务境外患者 72 万人次;2026 年 1—7 月其国际医疗中心业务量同比增长 17.8%。
  • Guangdong is accelerating wholly foreign-owned hospital pilots in Guangzhou and Shenzhen: six projects have reached landing intention and three have passed setting approval.
    广东正加快推进广州、深圳外商独资医院试点:已有 6 家项目达成落地意向,其中 3 家已通过设置审批。
  • Internationally oriented services are charged by the patient or their international commercial insurance, outside the basic medical insurance reimbursement scope, following international medical standards, processes and payment models.
    国际医疗服务按国际通行医疗技术标准、服务流程、管理体系和支付模式运营,费用由患者自付或国际商业保险支付,不纳入基本医保报销。
  • Guangzhou launched an international medical tourism service centre in April, issued 12 support measures, and in August released a cross-border insurance settlement platform enabling one-stop no-advance-payment settlement for foreign patients.
    广州 4 月揭牌国际医疗旅游服务中心并发布 12 条支持措施,8 月上线国际医疗跨境支付平台,实现境外患者就医免垫付一站式结算。
  • At national level, the National Health Commission confirmed in August that a second batch of wholly foreign-owned hospital pilot cities is being selected and that high-end specialist medical, rehabilitation and nursing are now in the encouraged catalogue nationwide.
    国家层面,国家卫生健康委 8 月确认正遴选第二批外商独资医院试点城市,并将高端专业医疗、康复、护理纳入全国鼓励范围。

Guangdong’s International Medical Services Pilot: Foreign-Patient Growth, Wholly Foreign-Owned Hospitals and What It Means for Healthcare Investors | 广东国际医疗服务试点:外籍患者增长、外商独资医院与医疗投资者的机会

The pilot and its early results

On 17 August 2026 the Guangdong Provincial Health Commission held its press conference for China’s Doctors’ Day and released the first substantive data on the province’s international medical services pilot. The pilot began in February 2026 when the provincial health commission, the medical security bureau and the drug administration jointly announced the first batch of 25 pilot hospitals, including Guangdong Provincial People’s Hospital, the First Affiliated Hospital of Sun Yat-sen University, Hong Kong University-Shenzhen Hospital and Zhuhai People’s Hospital. Since the launch, visits by foreign patients to the international and special-need medical departments of the 25 hospitals grew 95.6% year on year. The business model is explicitly international: services follow internationally accepted medical technical standards, service processes, management systems and payment models, targeting residents of Hong Kong, Macao and Taiwan, foreign nationals and overseas Chinese who pay out of pocket or through international commercial insurance, outside the scope of basic medical insurance reimbursement.

The scale and shape of demand

The pilot data show a large and growing cross-border patient pool. HKU-Shenzhen Hospital has treated patients from 129 countries and regions and served 720,000 foreign patients over three years; since joining the pilot, its international medical centre business grew 17.8% year on year in January–July 2026, with outpatient and check-up volumes up 16.4% and discharges up 33.5%, and Hong Kong patients accounting for 30% of outpatient and 20% of inpatient volumes. Guangdong’s position in the Greater Bay Area gives it a unique catchment: cross-border commuting workers, Hong Kong and Macao residents, and a deep stock of manufacturing-linked expatriate communities across the Pearl River Delta. For healthcare investors, the demand signal is that international-standard care priced outside the public insurance pool is a viable commercial segment in Guangdong, not a marginal one.

Wholly foreign-owned hospital acceleration

The most important development for foreign investors is the acceleration of wholly foreign-owned hospital pilots in Guangzhou and Shenzhen. Guangdong’s health commission reported that six projects have reached landing intention and three have passed setting approval. This follows the national framework: the September 2024 pilot notice and the November 2024 Plan for Expanding the Wholly Foreign-Owned Hospital Pilot, which set the conditions, requirements and procedures, and under which four wholly foreign-owned hospitals have already landed in Tianjin, Shanghai, Boao and Fuzhou. The National Health Commission confirmed in August 2026 that it is selecting a second batch of pilot cities, expanding from “point pilots” to regional rollout, and that the encouraged catalogue for foreign investment (2025 edition) now includes high-end specialist medical, rehabilitation and nursing nationwide. For a foreign hospital operator, Guangdong’s Guangzhou and Shenzhen are the most active frontier.

The stem-cell and gene-technology opening

A further dimension of the medical opening is technological. The National Health Commission confirmed in August 2026 that, in the Beijing, Shanghai and Guangdong free trade zones and the Hainan Free Trade Port, foreign-invested enterprises are permitted to conduct R&D and application of human stem-cell and gene-diagnosis and therapy technologies for the purpose of product registration and marketing, with approved products usable nationwide. For foreign biotech and cell-therapy companies, this converts the FTZ and Hainan pilots into a route to develop, register and market advanced therapies in China — subject to the full regulatory chain of human genetic resource administration, clinical trials (including international multicentre trials), drug registration and production licensing and ethics review. This is a significant expansion of the addressable market for foreign cell and gene therapy developers.

Guangzhou’s ecosystem building

Beyond the hospital pilots, Guangzhou is building the surrounding service ecosystem. In April 2026 the Guangzhou International Medical Tourism Service Centre was inaugurated, integrating the resources of 17 pilot hospitals in the city with the cultural-tourism and exhibition group; on the same day the city health commission issued 12 support measures for international medical services covering benchmark projects, resource clustering, talent attraction, payment convenience and TCM internationalisation. In August 2026, at the international medical innovation exchange and the Guangzhou Medical and Health Industry Expo, the Guangzhou Hospital Association’s International Medical Services Management Branch was established — the first industry management platform of its kind in the city — and a cross-border medical payment platform was released, enabling one-stop settlement for foreign patients without out-of-pocket advance payments through bank and insurer coordination. The city reports that foreign patients now come from 133 countries and regions, up from 90-plus before the tourism service centre opened, and that foreign patient volumes grew over 30% in the first half of the year to 260,000.

Practical guidance for healthcare investors

First, assess the pilot structure: wholly foreign-owned hospital entry requires setting approval, hospital licensing and alignment with the 2024 pilot conditions; the accelerated pace in Guangzhou and Shenzhen means the window is now. Second, understand the payment model: international services sit outside basic insurance, so pricing, insurance networks and cross-border settlement platforms are the commercial core. Third, for cell and gene therapies, evaluate the FTZ route in Guangdong (or Beijing, Shanghai, Hainan) for R&D and registration, and map the full regulatory chain early. Fourth, consider partnership with the 25 pilot hospitals — many are state-owned and are building international departments and tourism-service links, which offers a lighter entry than greenfield ownership. Fifth, monitor the second batch of pilot cities nationally and the encouraged-catalogue benefits (import duty, land, tax) that attach to encouraged categories. The Guangdong data prove the demand; the policy framework proves the intent; the remaining question for investors is execution speed and structure.

Outlook

Guangdong’s international medical pilot is the clearest demonstration yet that China’s healthcare opening has moved from policy text to commercial reality. Foreign-patient growth of nearly double in six months, wholly foreign-owned hospitals passing setting approval in Guangzhou and Shenzhen, a cross-border payment platform in operation and a provincial data trail — each of these would have been difficult to imagine two years ago. For foreign healthcare and biotech investors, the region is now a serious candidate for first entry into China’s mainstream private healthcare market.

Sources


广东国际医疗服务试点:外籍患者增长、外商独资医院与医疗投资者的机会

试点与早期成果

2026 年 8 月 17 日,广东省卫生健康委员会举行第九个中国医师节新闻发布会,公布国际医疗服务试点首批实质性数据。试点始于 2026 年 2 月,省卫健委、省医保局、省药监局联合公布首批 25 家试点医院名单,包括广东省人民医院、中山大学附属第一医院、香港大学深圳医院、珠海市人民医院等。启动以来,25 家医院国际医疗和特需医疗板块外籍人士就医人次同比增长 95.6%。业务模式明确国际化:按国际通行的医疗技术标准、服务流程、管理体系和支付方式运营,面向港澳台居民、外籍人士、海外华人等自费或持有国际商业保险的人群,费用不纳入基本医保报销。

需求的规模与形态

试点数据显示庞大且增长的跨境患者池。港大深圳医院已接诊来自 129 个国家和地区的患者,近三年服务境外患者 72 万人次;纳入试点后,2026 年 1—7 月国际医疗中心业务量同比增长 17.8%,门急诊和体检业务量增长 16.4%,出院量增长 33.5%,香港患者门急诊占比 30%、住院占比 20%。广东在大湾区的位置带来独特客源:跨境通勤人群、港澳居民、以及珠三角制造业沉淀的庞大外派社区。对医疗投资者,需求信号是:定价在公共医保池之外的国际标准医疗服务,在广东是可行的商业细分,而非边缘。

外商独资医院提速

对外国投资者最重要的进展是广州、深圳外商独资医院试点的加快。广东省卫健委通报,已有 6 家项目达成落地意向,其中 3 家已通过设置审批。这延续全国框架:2024 年 9 月开放试点通知与 2024 年 11 月《独资医院领域扩大开放试点工作方案》设定条件、要求与程序,首批 4 家外商独资医院已在天津、上海、博鳌、福州落地。国家卫生健康委 2026 年 8 月确认正遴选第二批试点城市,从”点状试点”向”区域推广”拓展;《鼓励外商投资产业目录(2025 年版)》已把高端专业医疗、康复、护理纳入全国鼓励范围。对外国医院运营者,广东的广州、深圳是最活跃的前沿。

干细胞与基因技术的开放

医疗开放的另一个维度是技术层面。国家卫生健康委 2026 年 8 月确认,在北京、上海、广东自贸试验区和海南自由贸易港,允许外商投资企业从事人体干细胞、基因诊断与治疗技术开发和应用,以用于产品注册上市和生产,经注册上市和批准生产的产品可在全国使用。对外国生物技术与细胞治疗企业,这使自贸试验区与海南试点转化为在中国开发、注册与上市先进疗法的路径——前提是走完整监管链:人类遗传资源管理、临床试验(含国际多中心临床试验)、药品注册上市、生产许可与伦理审查。这是外国细胞与基因治疗开发商可及市场的重大扩展。

广州的生态建设

在医院试点之外,广州正在建设周边服务生态。2026 年 4 月,广州国际医疗旅游服务中心揭牌,联动全市 17 家试点医院资源与文旅会展集团;同日市卫健委发布 12 条支持国际医疗服务创新举措,覆盖标杆打造、资源集聚、人才引育、支付便利与中医药国际化。2026 年 8 月,在国际医疗创新发展交流会暨广州医疗与健康产业博览会上,广州市医院协会国际医疗服务管理分会成立——全市首个专注国际医疗服务的行业管理平台——并发布国际医疗跨境支付平台,经政府、银行与保险机构协调实现境外患者就医免垫付一站式结算。广州报告境外患者来源地已从服务中心成立前的 90 多个国家和地区升至 133 个,上半年境外患者增长超 30%、达 26 万人次。

医疗投资者实操指引

其一,评估试点结构:外商独资医院进入须通过设置审批、医疗机构执业登记并符合 2024 年试点条件;广州、深圳提速意味着窗口期就在当下。其二,理解支付模式:国际服务在基本医保之外,定价、保险网络与跨境结算平台是商业核心。其三,细胞与基因疗法:评估广东(或北京、上海、海南)自贸试验区研发与注册路径,尽早梳理完整监管链。其四,考虑与 25 家试点医院合作——多数为公立,正在建设国际部与旅游服务链接,比绿地自有更轻的进入方式。其五,关注全国第二批试点城市与鼓励目录红利(进口关税、用地、税收)。广东数据证明了需求,政策框架证明了意图,留给投资者的问题是执行速度与结构。

展望

广东国际医疗试点是中国医疗开放从政策文本走向商业现实迄今最清晰的例证。六个月内外籍患者近翻倍增长、广州深圳外商独资医院通过设置审批、跨境支付平台投入运营、省级数据链条成形——每一项在两年前都难以想象。对外国医疗与生物科技投资者,该区域现已成为进入中国主流私立医疗市场的严肃首选地。

Sources

Segmented Pharmaceutical Production in China: A New Manufacturing Option for Foreign MAHs

  • On 15 May 2026 the revised Implementation Regulations of the Drug Administration Law took effect, with Article 32 expressly allowing segmented (split-site) production of qualifying innovative drugs under a unified quality-assurance system.
    2026年5月15日,新修订的《药品管理法实施条例》施行,其中第三十二条明确允许符合条件的创新药在统一质量保证体系下分段委托生产。
  • The State Drug Administration has separately worked on biological-product segmented production; the 2026 Action Plan to Stabilise and Optimise Foreign Investment now calls for detailed rules for cross-border segmented production of both biologicals and chemical drugs.
    国家药监局已就生物制品分段生产单独发文推进;2026年《利用外资固稳促优行动方案》进一步提出研究出台药品分段生产实施细则,便利境外药品上市许可持有人开展生物制品、化学药品跨境分段生产。
  • Segmented production applies to innovative drugs with special production-process or facility requirements, clinically urgent drugs, and drugs needed for public-health emergencies, as designated by the State Council.
    分段生产适用于生产工艺、设施设备有特殊要求的创新药,临床急需的药品,以及突发公共卫生事件急需或储备需要的药品等国务院规定情形。
  • The marketing authorisation holder (MAH) remains the single, final quality-responsible party and must build a unified quality-assurance system spanning all production sites.
    药品上市许可持有人(MAH)仍是唯一、最终的质量责任主体,必须建立覆盖药品生产全过程和全部生产场地的统一质量保证体系。
  • For foreign MAHs, the combination of segmented production and the FIE action plan opens a path to structure cross-border biologics and chemical manufacturing while keeping Chinese regulatory responsibility centralised.
    对外资MAH而言,分段生产与稳外资行动方案的组合,为跨境生物制品与化学药品生产布局开辟了路径,同时保持中国监管责任集中化。
  • Commercial insurers are also being encouraged to cover more innovative drugs and devices, and foreign-made drugs gain smoother entry into retail channels.
    政策同时鼓励保险公司将更多创新药械纳入商业保险保障范围,并便利外资企业生产的药品进入药品零售渠道。

Segmented Pharmaceutical Production in China: A New Manufacturing Option for Foreign MAHs | 中国药品分段生产:外资上市许可持有人的制造新选项

Why this matters now

Pharmaceutical manufacturing has traditionally meant one site, one product, one end-to-end process. China’s 2026 regulatory wave is deliberately unpicking that assumption. On 15 May 2026, the revised Implementation Regulations of the Drug Administration Law took effect, and Article 32 explicitly permits the segmented production of qualifying innovative drugs — where manufacturing steps run at different sites and potentially through different companies — as long as the marketing authorisation holder maintains a unified quality-assurance system. The move is paired with an explicit signal to foreign investors: the June 2026 Action Plan to Stabilise and Optimise Foreign Investment (issued by MOFCOM, NDRC and MOF) commits to detailed rules for cross-border segmented production of biological products and chemical drugs, building on the earlier biological-product segmented-production pilot. For a global pharma company with an approved innovative molecule, this changes how production for the Chinese market can be structured.

What segmented production covers

Article 32 of the revised Implementation Regulations permits segmented production for three categories: innovative drugs whose production process, equipment or facilities have special requirements; clinically urgent drugs requested by relevant State Council departments; and drugs needed for emergency response or stockpiling. The MAH may commission qualified production enterprises to handle separate production steps. Critically, the law does not decentralise responsibility: the MAH must establish a unified quality-assurance system covering the entire production process and all production sites, and remains the single final responsible party for product quality. The State Drug Administration’s inspection guidance for biological-product segmented production further requires the MAH to align quality-management systems across segment producers, apply quality-risk management to contamination and cross-contamination risks, and ensure the quality authorisation holder can base final release decisions on a full review of data from all segments.

The foreign-investment angle

The FIE Action Plan published in June 2026 explicitly says the authorities will move quickly to issue implementation rules for segmented production, to facilitate overseas drug marketing authorisation holders in carrying out cross-border segmented production of biologicals and chemical drugs. This is the first time the policy explicitly opens the door to cross-border arrangements — a Chinese plant handling one production step, an overseas site another. For foreign MAHs, the practical attraction is manufacturing flexibility: an API or biologic intermediate can be produced at the site with the best economics and IP-protection profile, with final formulation and packaging in China, while quality oversight remains anchored in one unified system. The same plan adds supporting measures: expanding the pilot scope for biotechnology and wholly foreign-owned hospitals, encouraging commercial insurers to cover more innovative drugs and devices, and easing foreign-made drugs into retail pharmacy channels.

Practical steps for foreign MAHs

  1. Map your portfolio. Identify molecules that qualify for segmented production — innovative drugs with special process or facility needs, clinically urgent products, or emergency/stockpile candidates.
  2. Decide the China anchor. Choose which production step will be performed in China and by which qualified manufacturer, and where the MAH quality-authorisation function will sit.
  3. Design the unified quality system. Draft the single quality-assurance framework covering all sites and segments, including technology transfer, change control, deviation handling and CAPA procedures.
  4. Engage the SDA early. Because implementation rules for chemical cross-border segmented production are still being drafted, use pre-submission consultation channels to align on expectations before committing investment.
  5. Review supply-chain economics. Model the tax, customs and logistics treatment of intermediates moving across borders, including bonded and duty-free options where available.
  6. Coordinate with insurance and retail access. Plan for how the product will reach patients — commercial insurance coverage and retail channel entry both affect market-access planning.

Risks and compliance notes

Segmented production is a permission, not a relaxation. The MAH’s single-responsibility rule means a failure at any segment is ultimately the MAH’s failure; contract manufacturers’ systems must be auditable and aligned. Foreign MAHs should also track the still-evolving implementation rules for chemical cross-border segmented production — until they issue, cross-border arrangements for small-molecule drugs should be structured conservatively. IP protection of process know-how across borders, GMP consistency between sites, and batch-release responsibilities all need contractual precision. Finally, the SDA’s on-site inspection and post-market supervision powers are unchanged, so documentation and traceability must satisfy the same standards as single-site production.


中国药品分段生产:外资上市许可持有人的制造新选项

为什么当下重要

药品生产传统上意味着”一个场地、一个产品、一条端到端流程”。中国2026年的监管浪潮正有意拆解这一假设。2026年5月15日,新修订的《药品管理法实施条例》施行,第三十二条明确允许符合条件的创新药分段生产——即制造环节在不同场地、甚至经由不同公司运行——只要上市许可持有人维护统一质量保证体系。该举措与对外资投资者的明确信号相配合:2026年6月商务部、国家发展改革委、财政部发布的《利用外资固稳促优行动方案》承诺研究出台生物制品与化学药品跨境分段生产实施细则,在早期生物制品分段生产试点基础上推进。对拥有获批创新分子的全球制药企业而言,这改变了中国市场的生产布局方式。

分段生产覆盖哪些情形

修订后《实施条例》第三十二条允许三类药品分段生产:生产工艺、设施设备有特殊要求的创新药;国务院有关部门提出的临床急需药品;以及应对突发公共卫生事件急需或储备需要的药品。MAH可以委托符合条件的生产企业承担不同生产步骤。关键在于,法律并未分散责任:MAH必须建立覆盖药品生产全过程和全部生产场地的统一质量保证体系,并作为产品质量唯一且最终的责任主体。国家药监局生物制品分段生产现场检查指南进一步要求MAH使各分段生产企业的质量管理体系有效衔接与统一,运用质量风险管理方法识别控制污染、交叉污染及差错风险,并确保质量受权人能基于对各分段数据的全面审核作出最终放行决定。

外资维度

2026年6月发布的稳外资行动方案明确提出,抓紧研究出台药品分段生产实施细则,便利境外药品上市许可持有人开展生物制品、化学药品跨境分段生产。这是政策首次明确为跨境安排敞开大门——中国工厂承担一个生产步骤,海外场地承担另一个。对外资MAH而言,实际吸引力在于制造灵活性:原料药或生物制品中间体可在经济性与知识产权保护最优的场地生产,最终制剂与包装放在中国,而质量监督仍锚定于一个统一体系。同一方案还附带了配套措施:扩大生物技术、外商独资医院开放试点区域范围,支持保险公司将更多创新药械纳入商业保险,并便利外资企业生产的药品进入零售药店渠道。

外资MAH的操作步骤

  1. 梳理产品组合。 识别符合分段生产条件的分子——生产工艺或设施有特殊要求的创新药、临床急需产品或应急/储备候选品。
  2. 确定中国锚点。 选择哪个生产步骤在中国、由哪家合格生产商执行,以及MAH质量受权职能设在何处。
  3. 设计统一质量体系。 起草覆盖全部场地与分段的单一质量保证框架,包括技术转移、变更控制、偏差处理与CAPA程序。
  4. 尽早与国家药监局沟通。 由于化学药品跨境分段生产实施细则仍在起草中,在投入投资前应利用预沟通渠道对齐预期。
  5. 审查供应链经济性。 建模中间体跨境流动的税收、海关与物流处理,在可行时考虑保税与免税选项。
  6. 协同保险与零售准入。 规划产品如何触达患者——商业保险覆盖与零售渠道进入都影响市场准入规划。

风险与合规提示

分段生产是许可,不是放松。MAH单一责任规则意味着任何分段的失败最终都是MAH的失败;合同生产商的体系必须可审计、可对齐。外资MAH还应跟踪仍在制定的化学药品跨境分段生产实施细则——在细则出台前,小分子药物跨境安排应保守设计。跨境工艺know-how的知识产权保护、场地间GMP一致性、批次放行责任都需要合同上的精确性。最后,药监局现场检查与上市后监管权限不变,因此文档与可追溯性必须满足与单一场地生产相同的标准。

Sources

  • 商务部 国家发展改革委 财政部《利用外资固稳促优行动方案》(商资发〔2026〕97号)——第三条”支持外资参与医药等产业高质量发展”(研究出台药品分段生产实施细则、便利境外MAH跨境分段生产):https://sxdofcom.shaanxi.gov.cn/fdi/yhzc/40265.jhtml
  • 商务部副部长凌激出席国新办发布会介绍利用外资固稳促优有关政策措施(王亚回应医药开放措施,生物制品分段生产试点、化学药品跨境分段生产细则):https://swj.wulanchabu.gov.cn/zxft/1994919.html
  • 中国医药创新促进会《药品管理法实施条例大家谈 在鼓励创新与严守底线间找到平衡》(第三十二条分段生产、MAH统一质量保证体系解读):https://www.phirda.com/artilce_43447.html
  • 山西省民营经济发展局官网《外资企业可重点关注哪些扩大准入领域?》(2026-08-10,摘自商资发〔2026〕97号:药品分段生产、生物技术和外商独资医院领域扩大开放):https://myj.shanxi.gov.cn/ztzl/bwbd/lywzgw/202608/t20260810_10196322.shtml

Wholly Foreign-Owned Hospital Pilot and Private Healthcare Opening

  • The “Pilot Work Plan for Expanding Opening in the Wholly Foreign-Owned Hospital Sector” (NHC, MOFCOM et al., Guowei Yizhengfa [2024] No. 36) permits wholly foreign-owned hospitals in nine provincial regions.
    国家卫生健康委、商务部等四部门《独资医院领域扩大开放试点工作方案》(国卫医政发〔2024〕36号)允许在9个省市设立外商独资医院。
  • The pilot covers Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and all of Hainan, explicitly excluding TCM institutions and the acquisition of public hospitals.
    试点范围涵盖北京、天津、上海、南京、苏州、福州、广州、深圳及海南全岛,明确排除中医类机构与并购公立医院。
  • Eligible hospitals are general, specialised or rehabilitation hospitals at tertiary level; blood-disease, psychiatric, infectious-disease and TCM hospitals are barred, and haematology is excluded from the practice scope.
    符合条件的医院类别为综合医院、专科医院、康复医院且级别为三级;禁止设立血液病、精神病、传染病、中医医院,且诊疗科目不得登记血液内科。
  • Foreign and HK/Macao/Taiwan physicians may be employed short-term, but Chinese (mainland) personnel must make up at least 50% of both management and professional staff.
    可按规定聘用外国及港澳台医师短期执业,但全院管理与卫生专业技术人员的中方(内地)人员占比均不得少于50%。
  • Approval sits with provincial health authorities (setting approval plus a five-year practice licence), with information systems connected to local regulatory platforms and data servers located in China.
    设置审批与执业登记由省级卫生健康行政部门核发(执业许可证有效期5年),信息管理系统须接入属地监管平台,服务器位于境内。
  • The plan folds into a broader “orderly expansion of opening in the medical sector” and offers foreign investors a greenfield route distinct from the previous Sino-foreign joint-venture hospital model.
    该方案属于”医疗领域有序扩大开放”整体部署,为外资提供区别于以往中外合资合作医院模式的新设独资路径。

Wholly Foreign-Owned Hospital Pilot and Private Healthcare Opening | 外资独资医院试点与社会办医扩大开放

Why this matters now

For foreign healthcare groups, China’s hospital market has long been accessible only through joint ventures or minority stakes under the Sino-foreign cooperative medical-institution framework. The late-2024 pilot to permit wholly foreign-owned hospitals changes that calculus: it creates a greenfield route for international operators to build and control a hospital on the mainland, bringing management models, clinical pathways and technology that complement the public system. The pilot is deliberately scoped — geographic, institutional and clinical guardrails are explicit — so the opportunity is real but bounded.

Market context: demand and the foreign-model case

The nine pilot regions are not arbitrary. They combine high openness, dense clusters of foreign enterprises and expatriates, and mature experience regulating foreign-funded medical institutions — exactly the conditions where demand for international-standard care is strongest. Foreign-invested hospitals are positioned to complement, not compete with, the public system: they target high-end and specialised demand, expatriate and cross-border patients, and technology- and service-model transfer that raises local standards. For provincial authorities, the pilot is also a service-environment upgrade that helps retain foreign talent and investment. The 50% mainland-personnel floor and the data-localisation duty, however, mean a foreign operator must build genuine local capability rather than merely import a brand. Realistic entrants therefore pair an international clinical franchise with a credible本地 workforce, IT and quality-system plan from day one.

The pilot framework

Issued by the National Health Commission, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and the National Disease Control and Prevention Administration (Guowei Yizhengfa [2024] No. 36, 1 November 2024), the plan authorises wholly foreign-owned hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and all of Hainan. TCM-category institutions are excluded, and acquiring public hospitals is not permitted. The nine regions were chosen for high openness, concentrated foreign enterprises and expatriates, and mature experience in regulating foreign-funded medical institutions.

Eligibility and operating conditions

The investor must be a legal person able to bear civil liability independently, with direct or indirect experience in healthcare investment and management, and must demonstrate international-leading management, models and equipment that supplement local supply. The hospital itself:

  • may be for-profit or non-profit;
  • must be a general, specialised or rehabilitation hospital at tertiary level — psychiatric, infectious-disease, blood-disease and TCM hospitals are prohibited;
  • may not register haematology as a practice department; and
  • may not conduct high-ethical-risk activities such as organ transplantation, assisted reproductive technology, prenatal screening/diagnosis, psychiatric inpatient care, or experimental cellular tumour therapies.

Foreign, HK/Macao and Taiwan physicians may be employed short-term, but Chinese (mainland) personnel must constitute at least 50% of both the management and the professional workforce. Information systems must connect to the local medical-service supervision platform, and electronic medical records and device data must be stored on servers located in China. Hospitals meeting medical-insurance rules may apply to join the designated insurance network and are encouraged to connect with domestic and international commercial health insurance.

Approval and supervision

Setting approval and practice registration are handled at the prefecture level for initial review and then by the provincial health authority, which issues the certificate of hospital establishment and the practice licence (valid five years, renewable). The licence is brought into the medical-quality safety-management system; hospitals are encouraged to participate in accreditation, and provincial and prefecture authorities conduct ongoing monitoring and coordinated supervision. Importantly, where the pilot conflicts with prior rules, the pilot plan prevails — giving it operative priority during the trial period.

Complementary openings across the medical sector

The hospital pilot is one move in a broader, sequenced opening of the healthcare and pharmaceutical sector. Around the same period, China removed or relaxed restrictions on foreign investment in several medical and aged-care sub-sectors, and the negative list has progressively shed items that previously capped foreign-invested enterprises in healthcare. Innovative-drug and medical-device access pathways have also been streamlined, and Greater Bay Area “medtech connexion” arrangements ease cross-boundary use of approved drugs and devices for residents. Read together, these signal a directional intent to let foreign capital and expertise enter where domestic supply is constrained or where international standards add value. Foreign groups should therefore map the hospital route against this wider roadmap — a hospital licence may pair naturally with device, pharma or senior-care ventures that share the same patient and regulatory ecosystem.

Practical steps for foreign investors

  1. Select a pilot region and confirm the hospital typology (general/specialised/rehabilitation, tertiary) against the exclusions.
  2. Prepare the investment and operating case showing international management, technology and capacity complementarity.
  3. Build the mainland workforce plan that satisfies the 50% Chinese personnel threshold across both management and clinical staff.
  4. Architect the IT and data posture — local servers, platform connectivity, and a data-governance stance consistent with China’s data-security and personal-information rules.
  5. Engage the provincial health authority early for the two-step approval, and plan for the five-year licence cycle and renewal.

Related reading

The hospital pilot sits inside a wider opening of the medical and pharmaceutical sector — from innovative-drug and device access to the negative list’s removal of certain restricted sub-sectors. Foreign groups should read the hospital route together with the broader healthcare-market-access roadmap.


外资独资医院试点与社会办医扩大开放

为何当下值得关注

对境外医疗集团而言,中国医院市场长期以来只能通过合资或少数股权路径进入(即中外合资合作医疗机构框架)。2024年底推出的”允许设立外商独资医院”试点改变了这一格局:它为国际运营方提供了一条在内地自主建设并控股医院的绿地路径,用以引入与公立医院体系互补的管理模式、临床路径与技术。该试点边界清晰——地理、机构与临床层面均设有明确护栏——因此机遇真实但有限定。

市场背景:需求与外资模式的逻辑

9个试点地区并非随意选取。它们兼具对外开放程度高、外资企业与外籍人员密集、监管外资医疗机构经验成熟等特征——恰恰是国际水准医疗需求最旺盛的条件。外商独资医院定位于与公立医院体系互补而非竞争:瞄准高端与专科需求、外籍及跨境患者,并以技术与管理模式转移提升本地标准。对省级政府而言,试点也是留住外资人才与投资的营商环境升级。但中方人员不少于50%与数据本地化义务,意味着外资运营方须建设真实的本地能力,而非仅引入品牌。务实的进入者因此从第一天起就将国际临床品牌与可信的本地人才、IT与质量体系计划相配对。

试点框架

由国家卫生健康委、商务部、国家中医药局、国家疾控局联合印发(国卫医政发〔2024〕36号,2024年11月1日),方案授权在北京、天津、上海、南京、苏州、福州、广州、深圳以及海南全岛设立外商独资医院。明确排除中医类机构,且不允许并购公立医院。选取这9个省市,是因为其对外开放程度高、外资企业与外籍人员集中,且积累了丰富的外资医疗机构管理经验。

资质与运营条件

境外投资者须为能够独立承担民事责任的法人,具有直接或间接医疗卫生投资与管理经验,并能提供国际先进的管理理念、模式与服务,以及国际领先的技术与设备,以补充或改善当地医疗服务能力。医院本身须满足:

  • 经营性质可为营利性或非营利性;
  • 类别为综合医院、专科医院、康复医院且级别为三级——禁止设立精神病、传染病、血液病、中医医院;
  • 诊疗科目不得登记血液内科;
  • 不得开展人体器官移植、人类辅助生殖、产前筛查与诊断、精神科住院治疗、肿瘤细胞治疗新技术试验性治疗等伦理风险较高的诊疗活动。

可按规定聘用外国及港澳台医师短期执业,但中方(内地)人员须占全院管理与卫生专业技术人员的均不少于50%。信息管理系统须接入属地医疗服务监管平台,电子病历与医用设备等信息存储服务器须位于中国境内。符合医保规定的医院可按程序申请纳入医保定点,并鼓励对接国内外商业健康保险。

审批与监管

设置审批与执业登记由地市级卫生健康行政部门初审、省级卫生健康行政部门核发设置医疗机构批准书与医疗机构执业许可证(有效期5年,期满可续)。医院纳入医疗质量安全管理范畴,鼓励参加医院评审评价,省级与地市级部门开展动态监测与协同监管。值得注意的是,原有规定与本试点方案不符的,以本方案为准——在试点期内具有操作优先性。

医疗行业更广维度的配套开放

医院试点只是医疗与医药行业有序、分批扩大开放中的一步。同一时期,中国在多个医疗与养老子行业取消或放宽了外资准入限制,负面清单也逐步删除了此前约束医疗卫生领域外商投资企业的条目。创新药与医疗器械准入路径同步简化,粤港澳大湾区”港澳药械通”等安排也便利了居民跨境使用已获批药品与器械。综合来看,这些举措释放出允许外资与专长进入供给受限或国际标准的确能增值领域的导向性意图。外资集团因此应将医院路径置于更宏观的路线图中研判——一张医院牌照可能天然与共享同一患者与监管生态的器械、药品或养老业务协同。

外资投资者实务步骤

  1. 选定试点地区,并对照排除项确认医院类型(综合/专科/康复,三级)。
  2. 准备投资与运营方案,论证国际管理、技术与能力互补性。
  3. 构建内地人才计划,满足管理与临床中方人员均不少于50%的要求。
  4. 设计IT与数据架构——境内服务器、平台对接,以及与数据安全、个人信息保护规则一致的数据治理立场。
  5. 尽早对接省级卫生健康行政部门完成两步审批,并规划5年证照周期与续期。

延伸阅读

医院试点位于医疗与医药行业更广开放版图之中——从创新药与医疗器械准入,到负面清单取消若干受限子行业。外资集团应将医院路径与更宏观的医疗服务市场准入路线图一并研读。

Sources

  • 国家卫生健康委、商务部、国家中医药局、国家疾控局:《独资医院领域扩大开放试点工作方案》(国卫医政发〔2024〕36号)— https://www.gov.cn/zhengce/zhengceku/202411/content_6990279.htm

China’s innovative-drug market and the foreign-pharma China playbook (2026)

  • China’s innovative-drug market is projected to exceed ¥1.3 trillion in 2026, with 2025 out-licensing deals reaching roughly US$135 billion and the first quarter of 2026 alone surpassing US$60 billion.
    2026 年中国创新药市场规模预计突破 1.3 万亿元;2025 年对外授权交易总额约 1357 亿美元,2026 年一季度即突破 600 亿美元。
  • The 2026 Government Work Report named biopharmaceuticals an “emerging pillar industry” for the first time, and a revised drug-administration regulation effective 15 May 2026 introduces six-year data protection and seven-year rare-disease exclusivity.
    2026 年政府工作报告首次将生物医药列为”新兴支柱产业”;2026 年 5 月 15 日施行的药品管理新规引入 6 年数据保护与 7 年罕见病市场独占。
  • Foreign pharma’s China role has shifted from “sell-in” to “license-in and co-develop”: multinationals now source early-stage assets from Chinese biotechs at an estimated 30%–40% of US development cost.
    外资药企在华角色已从”卖药”转向”引进与共创”:跨国药企以约为美国 30%–40% 的成本从中国 Biotech 采购早期管线。
  • AstraZeneca, Novartis, Roche, Sanofi and Lilly have announced deep localisation commitments — AstraZeneca alone plans over ¥100 billion by 2030 in China R&D and manufacturing.
    阿斯利康、诺华、罗氏、赛诺菲、礼来等已宣布深度本土化承诺——仅阿斯利康便计划 2030 年前在华投入超 1000 亿元用于研发与制造。
  • NMPA’s ICH alignment and priority-review pathways let China-discovered assets reach global markets faster, recasting China as an innovation “source” rather than only a “market.”
    国家药监局与 ICH 接轨及优先审评通道,使中国发现的资产更快走向全球,将中国从单纯的”市场”重塑为创新”源头”。
  • Practical entry levers for foreign players are license-in partnerships, local R&D centres, in-China manufacturing, and active NRDL/VBP engagement — not import-only models.
    外资企业的务实抓手是授权引进合作、本土研发中心、在华生产,以及主动参与医保目录/集采,而非单纯进口模式。

China’s innovative-drug market and the foreign-pharma China playbook (2026) | 2026 中国创新药市场与外资药企的中国策略

Overview

China’s innovative-drug sector has moved from “imitation-driven” to “innovation-exporting” in a matter of years, and 2026 is the year that shift became structural. The macroeconomic framing is unusually explicit: the 2026 Government Work Report named biopharmaceuticals an “emerging pillar industry” for the first time, placing the sector alongside integrated circuits, aerospace and the low-altitude economy. For foreign-invested pharmaceutical companies, the implication is that China is no longer just a sales territory to be supplied from overseas plants — it is now a discovery and development engine that multinationals are increasingly woven into.

This article maps the 2026 market size and deal landscape, explains why foreign pharma is “going Chinese” through license-in and co-development, details the localisation playbook foreign groups are deploying, and sets out practical entry levers. It is informational guidance, not regulatory or legal advice; confirm current rules with the NMPA and qualified PRC counsel.

Market context: scale, output and the BD boom

The market is large and still expanding. Industry estimates put China’s innovative-drug market at about ¥1.13 trillion in 2024, roughly ¥1.22 trillion in 2025, and a projected ¥1.3 trillion-plus in 2026. The growth story is less about volume than about structure: domestic innovative assets now dominate new approvals. The NMPA approved 76 innovative drugs in 2025 — up about 58% year-on-year, with domestically developed products accounting for more than 80% of the total. By mid-April 2026 the regulator had already cleared 13 innovative drugs for the year, including six first-in-class medicines, and by the end of the first quarter it had approved 10, eight of them domestic.

The pipeline is globally significant. At the end of 2025 China had 4,751 drugs in active research, about 33.7% of the global total — making it the largest single-country pipeline in the world. In next-generation modalities the lead is sharper still: as of late 2025 China contributed roughly 34% of early-stage next-generation-therapy pipelines globally, and led in antibody-drug conjugates (ADCs, ~54% share) and bispecific/multispecific antibodies (~48% share).

The defining commercial event of 2025–2026 is the outbound-licensing (BD) surge. Chinese drugmakers signed more than 150 out-licensing agreements in 2025 with total deal value above US$135 billion — the first time China surpassed the United States as the top source of such deals globally. The momentum accelerated into 2026: NMPA preliminary statistics show out-licensing deal value exceeded US$60 billion in the first three months of 2026, already nearly half of the prior full year’s total, and one industry tracker put Q1 2026 cross-border out-licensing at about US$61.4 billion, roughly 70% of global deal value that quarter. Deal structure is also evolving from single-asset licensing toward broader platform partnerships and NewCo structures that retain long-term upside for the Chinese originator.

Why foreign pharma is “going Chinese”

For most of the 2010s, a multinational’s China operation meant importing finished products and running local sales. That model is being replaced by deep integration into China’s discovery ecosystem. Three forces drive the change.

Cost-and-quality arbitrage. Bankers close to the market note that, for early-stage innovative assets, multinational “China sourcing” can cost an estimated 30%–40% of the equivalent US development cost while matching or beating efficacy — a combination that makes China a core pipeline source rather than a peripheral one. A senior JPMorgan healthcare banker has cited a multinational CFO’s view that, where the same pipeline can be sourced in China at a fraction of US cost with potentially superior outcomes, the choice is obvious.

A maturing, globally credible asset base. China’s regulatory system has converged with international standards: by the end of 2025 the NMPA had issued 71 ICH implementation announcements covering the full arc from early research to manufacturing quality control. Clinical-trial data generated in China under ICH-GCP now have a credible pathway to acceptance by the US FDA and EU EMA for global filings. China registered 5,173 drug trials in 2025, up nearly 99% from 2,602 in 2020, and patient recruitment cycles run shorter than the global average — a real operating-efficiency advantage for global programs.

Confidence expressed in cash. The headline license deals of 2025–2026 read like a roll-call of China-to-world transactions: CSPC signed a multi-project peptide partnership with AstraZeneca in January 2026; Sino Biopharm out-licensed a JAK/ROCK inhibitor to Sanofi for US$1.53 billion; Innovent extended its long-running Lilly alliance with a deal carrying US$350 million upfront and up to ~US$8.5 billion in milestones; and 3SBio’s PD-1/VEGF bispecific drew a record US$1.25 billion upfront from Pfizer. These are not one-off asset sales — they signal a structural re-rating of Chinese innovation as a global supply source.

The localisation playbook foreign groups are deploying

Foreign pharma is backing this strategic shift with capital and bricks. The pattern has moved from “light-asset sales offices” to “heavy-asset rooted platforms.”

R&D centres with real decision rights. AstraZeneca opened its sixth global strategic R&D centre in Beijing in October 2025 (a US$2.5 billion investment) and runs a parallel Shanghai engine; it plans to exceed ¥100 billion (about US$15 billion) of cumulative China R&D and manufacturing investment by 2030, including cell-therapy and radioligand-therapy bases in Shanghai and Guangzhou. Roche’s Shanghai innovation centre holds independent new-drug decision authority, with more than ten locally discovered molecules advanced to clinic, and its China Accelerator (launched 2021) had brought nearly 20 domestic biotech startups into its orbit by end-2024. Novartis operates three China R&D sites (Shanghai, Beijing, Suzhou) and, since 2024, has struck potential cooperation worth over ¥80 billion with Chinese innovators across cardiovascular, oncology, renal and neuroscience. Pfizer’s Beijing R&D centre, its third in China, anchors a “China-All-In” strategy embedding China in global early and pivotal Phase III programs.

Manufacturing upgraded to high-value categories. Sanofi broke ground on a Beijing insulin active-pharmaceutical-ingredient project (€1 billion) in October 2025 and opened a Chengdu innovation-and-operations centre in March 2026 (12,600 m², ~600 jobs). Lilly plans US$3 billion of China investment over the decade, including a US$200 million Suzhou expansion and Beijing/Shanghai incubators. Roche is building a Zhangjiang biopharma base (¥2.04 billion) and a Suzhou diagnostics plant (its largest single China investment). Novo Nordisk’s Tianjin site has drawn cumulative investment above ¥10 billion, with a further ¥4 billion quality-lab expansion completing in 2026.

Ecosystem co-creation over wholly-owned control. The dominant new mode is “capital + technology + ecosystem”: J&J’s JLABS Shanghai is among its largest global incubators; Bayer’s Zhangjiang co-creation platform targets small molecules, nucleic-acid drugs and AI drug discovery; AstraZeneca and CICC run a healthcare fund; and NewCo structures let Chinese originators retain upside while importing global capital and management. The logic, in one executive’s phrasing, is to “monetise current value while embedding into the global innovation network.”

2026 policy tailwinds

Beyond market pull, the policy environment in 2026 actively supports foreign participation.

  • Emerging-pillar status. The 2026 Government Work Report’s explicit naming of biopharmaceuticals as a pillar industry signals sustained, cross-ministry support rather than a one-off stimulant.
  • Stronger IP and exclusivity. A revised regulation implementing the Drug Administration Law took effect on 15 May 2026, introducing six-year regulatory data protection, seven-year market exclusivity for rare-disease drugs, and additional incentives for paediatric medicines — measures analysts say improve China’s attractiveness for global development partnerships.
  • Faster access. New-drug clinical-trial review timelines have been compressed from 60 to 30 working days, and time from approval to NRDL inclusion has shortened to about one year, narrowing the commercialisation gap that previously discouraged multinationals from launching novel assets in China first.
  • Openness under the 2026 action plan. The “Stabilising and Improving Foreign Investment” action plan (effective 1 July 2026) supports drug segmented-manufacturing rules and expands biotech and wholly-foreign-owned-hospital pilot regions — see the companion brief on pharma opening measures — reinforcing the message that foreign players are welcome across the value chain.

What foreign players should do next

  • Reframe China as a source, not just a market. Build or buy access to Chinese discovery assets through license-in, platform partnerships and NewCo structures rather than relying solely on imported products.
  • Plant R&D and manufacturing roots. Where the portfolio justifies it, establish or expand in-China R&D centres with local decision rights and high-value local manufacturing — this is now the expectation, not the exception.
  • Engage the NRDL/VBP reality early. Reimbursement and volume-based procurement determine commercial viability for most drugs; model them as part of the entry case, not as downstream marketing.
  • Leverage the regulatory convergence. Use ICH-aligned, China-generated data for global filings and consider China for simultaneous global trials to exploit speed and recruitment efficiency.
  • Protect the downside. Pair deeper integration with robust IP, data-protection and compliance posture, given the higher capital commitment localisation entails.

Common pitfalls

  • Treating China as a sales outpost. Groups that import only will miss the cost and speed advantages of Chinese discovery and risk being out-competed by locals and by peers who localised earlier.
  • Assuming overseas approval substitutes for China registration. An FDA/EMA licence does not register a product in China; a separate NMPA pathway with Chinese data is still required.
  • Under-resourcing local decision rights. Centres without real pipeline authority become expensive liaison offices; the winners grant China teams genuine development mandates.
  • Ignoring reimbursement until launch. NRDL and VBP outcomes — not the registration grant — often decide commercial success.
  • Over-concentrating in one modality. China’s strength is broad (ADC, bispecifics, GLP-1, cell therapy, radioligand), so a single-theme bet underuses the ecosystem.

Sources

  • National Medical Products Administration (NMPA) — official portal: https://www.nmpa.gov.cn
  • NMPA — English portal: https://english.nmpa.gov.cn
  • 国务院《利用外资固稳促优行动方案》(2026-06, 商资发〔2026〕97号): https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国务院新闻办发布会介绍利用外资固稳促优政策措施 (2026-06): https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm

Related reading

  • see also: Healthcare & pharma market access (NMPA) / 医疗医药准入(药监局)
  • see also: Pharma opening measures under the 2026 action plan / 医药产业开放新措施

2026 中国创新药市场与外资药企的中国策略

概述

中国创新药产业在数年间完成了从”仿创结合”到”创新输出”的跃迁,而 2026 年正是这一转变固化为结构性的时点。宏观层面的定调尤为罕见:2026 年政府工作报告首次将生物医药列为”新兴支柱产业”,与集成电路、航空航天、低空经济并列。对在华外资药企而言,这意味着中国已不再只是由海外工厂供货的销售疆域,而是跨国药企日益深度嵌入的发现与开发引擎。

本文梳理 2026 年的市场规模与交易格局,解释外资药企为何通过授权引进与共创走向”中国化”,剖析外资集团正在部署的本土化打法,并给出务实的进入抓手。本文仅为信息参考,不构成监管或法律意见;请以国家药监局及合格中国法律顾问确认最新规则。

市场语境:规模、产出与 BD 热潮

市场体量庞大且仍在扩张。行业估算显示,2024 年中国创新药市场规模约 1.13 万亿元,2025 年约 1.22 万亿元,2026 年预计突破 1.3 万亿元。增长故事的关键在于结构而非规模:国产创新资产如今主导新获批品种。国家药监局 2025 年批准 76 款创新药,同比增长约 58%,其中国产占比超过 80%。截至 2026 年 4 月中旬,监管方年内已放行 13 款创新药,含 6 款首创新药;到一季度末已批 10 款,其中 8 款为国产。

研发管线具备全球分量。2025 年底,中国在研创新药达 4751 个,约占全球总量的 33.7%,是全球单一国家中最大的在研管线。在下一代疗法领域领先更明显:截至 2025 年三季度,中国贡献了全球早期下一代疗法管线的约 34%,并在抗体偶联药物(ADC,约 54% 份额)与双抗/三抗(约 48% 份额)领域领跑。

2025–2026 年最具标志性的商业事件是出海授权的爆发。2025 年中国药企签署对外授权协议超 150 笔,总交易额逾 1357 亿美元,首次超越美国成为全球第一来源地。势头在 2026 年加速:国家药监局初步统计显示,2026 年前三个月对外授权交易额突破 600 亿美元,已接近上年全年的半数;有行业跟踪机构测算一季度跨境对外授权约 614 亿美元,约占当季全球交易额的 70%。交易结构也正从单资产授权,演进为更广泛的平台合作与保留长期上行空间的 NewCo 模式。

外资药企为何”中国化”

在 2010 年代的大部分时间里,跨国药企的中国业务意味着进口成品加本地销售。这一模式正被深度融入中国发现生态所取代,背后有三股力量。

成本与质量的套利。 贴近市场的投行人士指出,对早期创新资产而言,跨国药企的”中国采购”成本可低至美国开发成本的 30%–40%,且疗效相当或更优——这一组合使中国从边缘来源变为核心管线来源。某资深摩根大通医疗健康银行家援引一家跨国药企 CFO 的观点:当同一管线能以美国几分之一的成本在华获取且可能疗效更优时,选择不言自明。

成熟且全球可信的资产基础。 中国监管体系已与国际接轨:截至 2025 年底,国家药监局已发布 71 项 ICH 实施公告,覆盖从早期研究到生产质量控制的完整链条。按 ICH-GCP 在中国生成的数据,已具备被美国 FDA、欧洲 EMA 接受并用于全球申报的可行路径。2025 年中国登记药物临床试验 5173 项,较 2020 年的 2602 项增长近 99%,且患者入组周期短于全球平均——这对全球研发项目是真实的运营效率优势。

以资金表达的信心。 2025–2026 年的重磅授权交易堪称中国走向世界的清单:2026 年 1 月石药与阿斯利康签署多肽多项目合作;中国生物制药以 15.3 亿美元将 JAK/ROCK 抑制剂授权给赛诺菲;信达延展与礼来的长期联盟,交易含 3.5 亿美元首付款及最高约 85 亿美元里程碑;三生制药 PD-1/VEGF 双抗更从辉瑞处拿下 12.5 亿美元创纪录首付款。这些不是一次性资产出售,而是对中国创新作为全球供给源的系统性重估。

外资集团正在部署的本土化打法

外资药企正以资本与实体落地为这一战略转向背书。路径已从”轻资产销售办公室”升级为”重资产扎根平台”。

拥有真实决策权的研发中心。 阿斯利康 2025 年 10 月启用北京全球战略研发中心(25 亿美元投资),并与上海引擎并列;计划 2030 年前在华研发与制造累计投入超 1000 亿元,含上海细胞治疗与广州放射偶联药物基地。罗氏上海创新中心拥有独立新药决策权,已有十余款本土发现分子推进至临床;其 2021 年启动的中国加速器截至 2024 年底已引入近 20 家本土 Biotech。诺华在华运营上海、北京、苏州三处研发站点,且自 2024 年以来与本土创新者的潜在合作规模超 800 亿元,覆盖心血管、肿瘤、肾脏与神经科学。辉瑞北京研发中心作为其中国第三家研发中心,承载将中国纳入全球早期与关键三期同步开发的”China-All-In”战略。

向高价值品类升级的制造。 赛诺菲 2025 年 10 月在京启动胰岛素原料药项目(10 亿欧元),并于 2026 年 3 月启用成都创新与运营中心(1.26 万平方米、约 600 个岗位)。礼来计划十年内在华投资 30 亿美元,含 2 亿美元苏州扩建及北京/上海孵化器。罗氏正建设张江生物制药基地(20.4 亿元)与苏州诊断工厂(其在华最大单笔投资)。诺和诺德天津基地累计投资已超百亿元,并追加 40 亿元质量实验室扩建于 2026 年完工。

以生态共创取代全资控制。 主流新模式是”资本+技术+生态”:强生 JLABS 上海是其全球规模最大的孵化器之一;拜耳张江共创平台聚焦小分子、核酸药物与 AI 药物发现;阿斯利康与中金设立医疗健康基金;NewCo 结构让中国原创方保留上行空间,同时引入全球资本与管理。用一位高管的话说,其逻辑是”在兑现当期价值的同时,嵌入全球创新网络”。

2026 年政策顺风

除市场拉力外,2026 年的政策环境主动支持外资参与。

  • 支柱地位。 2026 年政府工作报告明确将生物医药列为支柱产业,意味着跨部委的持续支持,而非一次性刺激。
  • 更强 IP 与独占期。 落实《药品管理法》的修订条例于 2026 年 5 月 15 日施行,引入 6 年数据保护、7 年罕见病市场独占及儿科用药额外激励——分析人士认为这提升了中国对全球开发合作的吸引力。
  • 更快可及。 新药临床试验审评时限已从 60 个工作日压缩至 30 个,从获批到纳入医保目录的时间缩短至约一年,收窄了此前阻碍跨国药企在华首发新品的商业化落差。
  • 行动方案下的开放。 《利用外资固稳促优行动方案》(2026 年 7 月 1 日落地)支持药品分段生产细则并扩大生物技术、外商独资医院试点区域——详见姊妹篇《医药产业开放新措施》——强化外资可全程参与价值链的信号。

外资企业应做的下一步

  • 将中国重构为源头而非仅市场。 通过授权引进、平台合作与 NewCo 结构建立或买断对中国发现资产的触达,而非仅依赖进口产品。
  • 植下研发与制造的树根。 若组合justify,应设立或扩地在华研发中心并赋予本地决策权,并布局高价值本地制造——这已成为预期,而非例外。
  • 早介入医保/集采现实。 报销与带量采购决定多数药品的商业可行性,应作为进入论证的一部分,而非下游营销问题。
  • 借力监管接轨。 用 ICH 接轨、中国生成的数据支撑全球申报,并考虑以中国承接全球同步试验,以利用速度与入组效率。
  • 守住下行。 因本土化意味着更高资本承诺,须配套稳健的 IP、数据保护与合规体系。

常见误读

  • 把中国当销售前哨。 仅做进口的企业将错失中国发现的成本与速度优势,并被本土企业及更早本土化的同行反超。
  • 以为境外批准可替代中国注册。 FDA/EMA 许可不等于在中国注册;仍需走完国家药监局的独立路径并常需中国数据。
  • 本地决策权投入不足。 没有真实管线权限的中心沦为昂贵联络处;赢家授予中国团队真正的开发授权。
  • 上市前才想报销。 决定商业成败的常是医保目录与集采结果,而非注册批件。
  • 单一赛道过度集中。 中国优势面广(ADC、双抗、GLP-1、细胞治疗、放射配体),单主题下注浪费了生态。

来源

  • 国家药品监督管理局(NMPA)——官方门户:https://www.nmpa.gov.cn
  • NMPA——英文门户:https://english.nmpa.gov.cn
  • 国务院《利用外资固稳促优行动方案》(2026-06,商资发〔2026〕97号):https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国务院新闻办发布会介绍利用外资固稳促优政策措施(2026-06):https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm

相关阅读

  • 参见:医疗医药准入(药监局) / Healthcare & pharma market access (NMPA)
  • 参见:医药产业开放新措施 / Pharma opening measures under the 2026 action plan

China Expands 240-Hour Visa-Free Transit to 57 Countries: New Options for Business Travelers (August 2026)

  • From 20 August 2026, nationals of Kyrgyzstan and Vietnam can use China’s 240-hour visa-free transit policy and Hainan’s 30-day visa-free entry policy, raising the eligible country counts to 57 and 61 respectively.
    自 2026 年 8 月 20 日起,吉尔吉斯斯坦、越南公民可适用 240 小时过境免签与海南 30 天入境免签政策,两项政策的适用国家分别增至 57 国与 61 国。
  • Eligible travellers holding ordinary passports and confirmed interline tickets can enter through any of 65 open ports, including Beijing and Shanghai, and stay up to 240 hours (10 days) within designated areas.
    持普通护照与确定日期及行程联程客票的旅客,可从北京、上海等 65 个对外开放口岸免签入境,并在规定区域内免签停留不超过 240 小时。
  • Vietnamese and Kyrgyz nationals with ordinary passports may enter through any open port of Hainan and stay up to 30 days within the province.
    吉、越两国公民持普通护照可由海南省对外开放口岸入境,在海南省行政区域内免签停留不超过 30 天。
  • The visa-free stays cover tourism, business, visits and family visits; work, study and news reporting still require a visa obtained before arrival.
    免签停留可从事旅游、商贸、访问、探亲等短期活动;工作、学习、新闻采访等仍需在来华前办妥签证。
  • Vietnam was China’s fourth-largest source of inbound travellers in H1 2026, and border traffic between the two countries has grown sharply, making the expansion commercially significant.
    2026 年上半年越南是中国第四大入境游客来源国,两国间口岸往来快速增长,本次扩围的商业意义显著。
  • For foreign-invested employers and business travellers, the expansion lowers entry friction for meetings, inspections and short assignments, but residence permit and work-permit routes remain unchanged.
    对外资企业与商务旅客而言,本次扩围降低了会议、考察与短期任务的入境门槛,但居留许可与工作许可路径保持不变。

China Expands 240-Hour Visa-Free Transit to 57 Countries: New Options for Business Travelers (August 2026) | 中国 240 小时过境免签扩至 57 国:外籍商务旅客的新选项(2026 年 8 月)

Why this matters now

On 20 August 2026, the National Immigration Administration (NIA) announced that nationals of Kyrgyzstan and Vietnam would become eligible for China’s 240-hour visa-free transit policy and Hainan’s 30-day visa-free entry policy with immediate effect. The 240-hour transit scheme now covers 57 countries and the Hainan scheme 61 countries. The change is part of a steady widening of China’s short-term entry facilitation since the scheme was extended from 72/144 hours to 240 hours in December 2024, and it matters for multinational companies because two neighbouring, high-volume source markets — Vietnam and Central Asia’s Kyrgyzstan — now enjoy visa-free access for precisely the kind of short, business-driven trips that previously required advance visa arrangements.

What the August 2026 expansion means in practice

Under the NIA announcement (No. 4 of 2026), citizens of Kyrgyzstan and Vietnam who hold an ordinary passport and a confirmed interline ticket with a fixed date and itinerary, and who are transiting through China to a third country or region, may enter visa-free through any of the 65 designated open ports, including Beijing and Shanghai, and stay up to 240 hours in the designated areas. The same two nationalities may alternatively enter through any open port of Hainan Province and stay up to 30 days. The eligible activities are tourism, business, visits and family visits. Work, study and news reporting still require an advance visa, and travellers who plan to stay beyond the limits or leave the designated areas must use the ordinary visa or residence-permit route.

For foreign-invested enterprises, the practical benefit is lower friction for short trips: factory inspections, supplier meetings, trade-fair attendance, client visits and board-level discussions that fall within 10 days can now be handled visa-free for citizens of the 57 covered countries. Vietnam was China’s fourth-largest source of inbound travellers in the first half of 2026, after Korea, Russia and Malaysia, and the Hekou port on the Yunnan–Vietnam border alone recorded more than 4 million border crossings by mid-August. Kyrgyzstan’s Torugart port on the Xinjiang border also saw a 60% year-on-year increase in trips in the first quarter of 2026, so the policy is expected to accelerate both business and tourism traffic.

Practical steps for employers and travellers

  1. Confirm eligibility before booking. Check that the traveller’s nationality is on the 57-country list and that the itinerary is a genuine transit to a third country or region with a confirmed onward ticket.
  2. Stay within the 240-hour window and the designated area. Overstaying or travelling outside the approved region converts a facilitation into an immigration compliance issue; the 10-day cap counts from arrival.
  3. Choose the right route for longer stays. If the purpose is work, study or journalism, or the stay exceeds the visa-free limit, apply for the appropriate visa or work/residence permit before arrival — the visa-free schemes do not replace these.
  4. For Hainan-specific travel, note that the 30-day entry is limited to the province; leaving Hainan for the mainland requires an appropriate permit or visa.
  5. Keep documents consistent. Immigration officers verify the ordinary passport and the interline ticket; name and date mismatches can cause denial at the port.
  6. Plan compliance updates. Multinational HR and mobility teams should update internal travel policies and visa matrices so that short business trips to China use the right, fastest legal channel.

Compliance notes

The expansion is a facilitation of short-term entry, not a change to China’s work and residence framework. Foreign employees who enter visa-free cannot simply begin working in China; the work-permit and work-type residence permit route, and the foreigner work permit classification system, remain mandatory for employment. Employers should also be aware that the transit area restrictions differ by port group, and that the authorities retain the right to require a visa when circumstances suggest the traveller does not genuinely intend to transit. Finally, policies at the operational level — port lists, airline cooperation and regional implementation — can be adjusted by the NIA without notice, so verify the current rules before each trip. For 2026 planning, treat the August expansion as a baseline and re-check before each itinerary, because the 240-hour and Hainan schemes continue to evolve in both country coverage and port lists.


中国 240 小时过境免签扩至 57 国:外籍商务旅客的新选项(2026 年 8 月)/ China Expands 240-Hour Visa-Free Transit to 57 Countries: New Options for Business Travelers (August 2026)

为什么当下重要

2026 年 8 月 20 日,国家移民管理局发布公告,自当日起对吉尔吉斯斯坦、越南公民实施 240 小时过境免签政策和海南 30 天入境免签政策。至此,240 小时过境免签政策适用国家增至 57 国,海南 30 天入境免签政策适用国家增至 61 国。此次调整是 2024 年 12 月免签停留时长从 72/144 小时延长至 240 小时后,中国持续放宽短期入境的又一步。对跨国企业而言,两个邻近且客流量大的来源市场——越南与中亚的吉尔吉斯斯坦——如今对这类过去需要提前办签的短期商务差旅,享受免签入境。

2026 年 8 月扩围的实操含义

根据国家移民管理局 2026 年第 4 号公告,吉尔吉斯斯坦、越南公民持普通护照和确定日期及行程的联程客票,从中国过境前往第三国或地区,可从北京、上海等 65 个对外开放口岸免签入境,并在规定区域内免签停留不超过 240 小时。两国公民也可选择持普通护照从海南省对外开放口岸入境,在海南省行政区域内免签停留不超过 30 天。适用上述政策的来华活动包括旅游、商贸、访问、探亲等短期活动;工作、学习、新闻采访等仍应在来华前办妥签证,计划超期停留或离开规定区域的旅客须走普通签证或居留许可路径。

对外资企业而言,实际好处在于短期差旅摩擦降低:工厂考察、供应商会谈、参展、客户拜访、董事会讨论等 10 天以内的行程,覆盖名单内 57 国公民现在可以免签完成。2026 年上半年越南是中国第四大入境游客来源国(仅次于韩国、俄罗斯、马来西亚),仅云南河口口岸与越南的出入境人数到 8 月中旬累计已超 400 万人次;新疆的吐尔尕特口岸一季度出入境人次同比增 60%。预计该政策将同时带动商务与旅游往来。

雇主与旅客的操作步骤

  1. 预订前确认资格。 核验旅客国籍是否在 57 国名单内,且行程确为前往第三国或地区的过境,并持有确认的联程机票。
  2. 控制 240 小时与限定区域。 超期停留或离开批准区域会使便利措施变成出入境合规问题;10 天上限自入境起算。
  3. 更长的停留选择正确路径。 若目的为工作、学习或新闻采访,或停留超出免签时限,应在来华前申请相应签证或工作/居留许可——免签政策不替代这些安排。
  4. 海南专项行程注意。 30 天入境限定在省内;离开海南进入内地需相应许可或签证。
  5. 保持证件信息一致。 边检核验普通护照与联程客票;姓名、日期不符可能导致口岸拒绝入境。
  6. 同步更新合规材料。 跨国 HR 与差旅团队应更新内部出行政策与签证矩阵,确保赴华短期商务行程走正确、最快的合法通道。

合规提示

本次扩围是短期入境的便利化,不是中国工作与居留框架的变化。以免签身份入境的外籍员工不能直接开始在华工作;工作许可、工作类居留许可以及外国人工作许可分类管理路径对就业仍然强制适用。雇主还应留意,过境停留区域限制因口岸群而异,且当情况显示旅客并非真实过境时,主管机关保留要求办理签证的权力。最后,口岸名单、航司合作与地区落地细则可能由国家移民管理局随时调整,每次出行前应核实现行规则。

Sources

China’s 240-Hour Visa-Free Transit: Ports, Provinces and Business-Travel Practice (2026)

  • China’s 240-hour visa-free transit lets eligible nationals of 55 countries transit to a third destination via 65 ports across 24 provincial-level regions, staying up to 10 days without a visa.
    中国240小时过境免签允许55国合资格人员经24个省区市的65个口岸前往第三国(地区),免签停留最长10天。
  • In its first year the policy drove 40.6 million inbound foreign arrivals (+27.2% yoy), with 240-hour users up 60.8% versus the pre-optimisation baseline.
    实施首年带动全国各口岸入境外籍人员4060万人次(同比+27.2%),240小时适用人数较优化前增60.8%。
  • The November 2025 expansion added Guangzhou, Hengqin, Zhongshan, the HK–Zhuhai–Macao Bridge and West Kowloon as new ports, raising the total from 60 to 65.
    2025年11月扩围新增广州、横琴、中山、港珠澳大桥及西九龙等口岸,总数由60增至65。
  • Eligible activities during stay include tourism, business, visiting and family; the stay area spans 24 provinces, with some provinces open province-wide.
    停留期间可从事旅游、商务、访问、探亲等活动;停留区域覆盖24个省区,部分省份全省开放。
  • A separate unilateral visa exemption for 40+ countries was extended to 31 December 2026, complementing the transit scheme for short visits.
    面向40多个国家的单边免签已延长至2026年12月31日,与过境方案形成短期访问互补。
  • Practical step: confirm nationality and onward-ticket, enter via a designated port, and respect the stay area and 240-hour clock for business visits.

实操建议:确认国籍与联程机票,经指定口岸入境,并遵守停留区域与240小时时限以商务访问。

China’s 240-Hour Visa-Free Transit: Ports, Provinces and Business-Travel Practice (2026) | 240小时过境免签扩围:口岸、适用省份与商务旅行实务(2026)

China’s transit visa-free programme is one of the most tangible openings for business travellers. The 240-hour (10-day) visa-free transit now covers eligible nationals of 55 countries entering via 65 ports in 24 provincial-level regions for a stay of up to 10 days before proceeding to a third country or region. For foreign investors doing site visits, trade fairs and partner meetings, the scheme removes a major friction point.

How the policy expanded

The National Immigration Administration (NIA) first extended the stay from 72/144 hours to 240 hours and widened the ports and areas in a major relaxation. A November 2025 update added Guangzhou, Zhuhai’s Hengqin and Zhongshan, the Hong Kong–Zhuhai–Macao Bridge and the West Kowloon Station of the Guangzhou–Shenzhen–Hong Kong Express Rail Link, lifting the eligible ports from 60 to 65. The stay area grew to 24 provincial-level regions; Anhui, Hainan and Guizhou are open province-wide, while Shanxi (Taiyuan/Datong) and Jiangxi (Nanchang/Jingdezhen) are partially open. Travellers may move across the designated areas of the 24 regions.

Who and what

Eligible persons are nationals of 54–55 specified countries transiting to a third destination. During the stay they may engage in tourism, business, visiting and family activities — which covers the typical foreign-invested-enterprise scenario of a short inspection, a trade fair or a board meeting. A separate unilateral visa exemption for more than 40 countries (including France, Germany, Italy, the Netherlands, Spain and Sweden) was extended to 31 December 2026, giving another channel for short visits.

The impact

One year after implementation, inbound foreign arrivals through all ports reached 40.6 million (+27.2% year-on-year), and 240-hour transit users grew 60.8% over the pre-optimisation baseline. The NIA also let foreign travellers complete entry cards online before arrival from 20 November 2025. The momentum reflects both demand and China’s push for “institutional opening” in personnel exchange.

Practical business-travel steps

  1. Confirm eligibility. Check that your nationality is on the 55-country list and that you hold an onward ticket to a third country/region.
  2. Enter at a designated port. Use one of the 65 ports; confirm the specific terminal (e.g., the bridge or rail station) accepts transit.
  3. Respect the stay area. Travel only within the 24 designated regions; note province-wide vs partial openings.
  4. Mind the clock. The 240 hours run from entry; plan departure before expiry.
  5. Keep documents. Carry the onward ticket and accommodation/business-meeting proof if asked.

240小时过境免签扩围:口岸、适用省份与商务旅行实务(2026)

中国的过境免签是商务旅客感受最直观的开放举措。240小时(10天)过境免签现覆盖55国合资格人员,经24个省区市的65个口岸入境,前往第三国或地区前可免签停留最长10天。对来华考察、参展、会晤合伙人的外资人士而言,该政策消除了主要摩擦点。

政策如何扩围

国家移民管理局先将停留时间由72/144小时延长至240小时,并在一次大幅优化中扩大口岸与区域。2025年11月更新新增广州、珠海横琴、中山、港珠澳大桥及广深港高铁西九龙站等口岸,使适用口岸由60增至65。停留区域增至24个省区市;安徽、海南、贵州全省开放,山西(太原/大同)、江西(南昌/景德镇)部分开放。旅客可在24个区域的指定范围内跨省旅行。

适用对象与活动

合资格者为前往第三国(地区)的54–55个指定国家人员。停留期间可从事旅游、商务、访问、探亲——涵盖外商投资企业典型的短期考察、参展或董事会场景。面向40多个国家的单边免签(含法国、德国、意大利、荷兰、西班牙、瑞典等)已延长至2026年12月31日,为短期访问提供另一通道。

实施成效

实施一年来,全国各口岸入境外籍人员达4060万人次(同比+27.2%),240小时适用人数较优化前增60.8%。国家移民管理局自2025年11月20日起允许外籍旅客抵前在线填妥入境卡。这一势头既反映需求,也体现中国在人员往来领域”制度型开放”的推进。

商务旅行实操步骤

  1. 确认资格。 核对国籍在55国名单内,并持前往第三国(地区)的联程机票。
  2. 经指定口岸入境。 使用65个口岸之一;确认具体场站(如大桥或高铁站)受理过境。
  3. 遵守停留区域。 仅在24个指定区域内旅行;注意全省开放与部分开放之别。
  4. 留意时限。 240小时自入境起算,须在期满前离境。
  5. 备妥证件。 随身带联程机票及住宿/商务会晤证明以备查验。

What Changed in the Latest Round

The November 2025 relaxation was the most significant since the programme began. It added Guangzhou’s airports, Zhuhai’s Hengqin and Zhongshan, the Hong Kong–Zhuhai–Macao Bridge and the West Kowloon Station of the Guangzhou–Shenzhen–Hong Kong Express Rail Link as new 240-hour transit ports, raising the total from 60 to 65. The stay area expanded to 24 provincial-level regions, with Anhui, Hainan and Guizhou open province-wide. Alongside this, the unilateral visa exemption for more than 40 countries was extended to 31 December 2026, and foreign travellers were allowed to complete entry cards online before arrival from 20 November 2025. For business visitors, the practical effect is a near-seamless short stay for site visits, trade fairs and board meetings without a formal visa.

本轮2025年11月的放松是该项目启动以来力度最大的一次。新增广州机场、珠海横琴与中山、港珠澳大桥、广深港高铁西九龙站等为240小时过境口岸,总数由60增至65。停留区域扩至24个省区市,安徽、海南、贵州全省开放。与此同时,面向40多个国家的单边免签延长至2026年12月31日,自2025年11月20日起外籍旅客可抵前在线填妥入境卡。对商务访客而言,实地考察、参展与董事会等短期停留近乎无缝,无需正式签证。

Practitioner Quick Reference

  • 55 countries, 65 ports, 24 regions, 240 hours: the headline parameters of the transit scheme.
    55国、65口岸、24区域、240小时:过境方案的核心参数。
  • New ports: Guangzhou, Hengqin, Zhongshan, the HK–Zhuhai–Macao Bridge and West Kowloon.
    新增口岸:广州、横琴、中山、港珠澳大桥、西九龙。
  • Activities allowed: tourism, business, visiting and family — covers inspections, fairs and meetings.
    允许活动:旅游、商务、访问、探亲——涵盖考察、参展与会议。
  • Unilateral visa-free complements: 40+ countries exempt to 31 Dec 2026 for short visits.
    单边免签互补:40多国免签至2026年12月31日,适用短期访问。
  • Online entry cards: complete the card before arrival from 20 Nov 2025.
    在线入境卡:自2025年11月20日起可抵前填妥。

Common Pitfalls

  • Wrong port: entering via a non-designated port breaks the transit eligibility.
    口岸不符:经非指定口岸入境即丧失过境资格。
  • Overstaying the area: leaving the 24 designated regions violates the condition.
    越出区域:离开24个指定区域即违规。
  • Missing the clock: the 240 hours run from entry; plan the outbound leg in time.
    忽视时限:240小时自入境起算,须及时安排离境行程。

2026 Watchlist

  • Further port additions: more airports and rail stations may be added to the 65-port list.
    口岸再增:更多机场与高铁站或纳入65口岸清单。
  • Unilateral visa-free expansion: the 40+ country list may extend beyond 31 Dec 2026.
    单边免签扩国:40多国免签名单或延至2026年12月31日之后。
  • Entry-card digitisation: online pre-arrival cards may expand to more traveller types.
    入境卡数字化:抵前在线填卡或扩至更多旅客类型。

Key Figures

  • 55 countries: nationalities eligible for the 240-hour transit scheme.
    55国:适用240小时过境免签的国家。
  • 65 ports: designated entry ports after the November 2025 expansion.
    65个口岸:2025年11月扩围后的指定入境口岸。
  • 24 regions: provincial-level areas open for the stay.
    24个区域:开放停留的省区市。
  • 40.6 million: inbound foreign arrivals in the first year (+27.2% yoy).
    4060万人次:实施首年入境外籍人员(同比+27.2%)。

Sources

Visa Facilitation for Business Visitors to China in 2026: Transit, Unilateral and Port-Visa Options Compared

  • China now offers business visitors three layered, non-exclusive entry conveniences — 240-hour transit visa-free, unilateral visa-free for 50 countries, and port visa / APEC Business Travel Card — and choosing the right one depends on itinerary, nationality and purpose.
    中国目前为商务访客提供三层叠加、互不排斥的入境便利——240小时过境免签、对50国的单方面免签,以及口岸签证与APEC商务旅行卡;正确选择取决于行程、国籍与目的。
  • The 240-hour (10-day) transit visa-free scheme covers 55 countries, 65 open ports across 24 provinces, and permits tourism, business, visits and family reunions during the stay.
    240小时(10天)过境免签覆盖55个国家、24个省份的65个开放口岸,停留期间可从事旅游、商务、访问与探亲活动。
  • As of 17 February 2026, China applies unilateral visa-free entry to 50 countries for stays up to 30 days for business, tourism, family visits, exchanges and transit.
    截至2026年2月17日,中国对50个国家实施单边免签,因经商、旅游观光、探亲访友、交流访问、过境事由来华可免签停留不超过30日。
  • Regional entry visa-free schemes — Hainan (59 countries, 30 days), cruise tours, ASEAN tour groups and HK/Macau-organsied foreign tour groups into the Greater Bay Area or Hainan — open targeted corridors for business-and-leisure combinations.
    区域性入境免签——海南(59国、30天)、邮轮免签、东盟旅游团免签,以及经港澳旅行社组团免签进入大湾区或海南——为”商务+休闲”组合打开了定向通道。
  • Port visas let qualifying foreign business visitors obtain a visa on arrival at designated ports when an invitation letter and supporting documents are ready, and the APEC card enables multi-year, multi-economy transit.
    口岸签证允许符合条件的外国商务人员凭邀请函等证明材料在指定口岸落地办证,APEC商务旅行卡则实现多年期、多经济体的通行。
  • None of these substitutes for a work or study visa; paid employment, study and news reporting still require prior approval, and overstayers face fines, detention and future-entry bans.
    上述任何一项都不能替代工作或学习签证;有偿就业、留学与新闻采访仍须事先批准,逾期停留将面临罚款、拘留与未来入境限制。

Visa Facilitation for Business Visitors to China in 2026: Transit, Unilateral and Port-Visa Options Compared | 2026年外国商务人员来华免签与口岸签证便利:过境免签、单方面免签与口岸签证对照

Why this matters now

Easing the movement of people is now a stated tool of investment promotion. The *Action Plan for Stabilising and Optimising Foreign Investment* (MOFCOM, NDRC and MOF, Document No. 97 of 2026) explicitly lists transit visa-free, tax-refund-on-departure and cross-border payment measures among the ways China optimises the internationalised business environment. For the foreign executive weighing a week of client meetings, a factory inspection or a board session in China, the visa question is often the first friction point. The good news: the default answer is increasingly “you may not need a visa at all,” provided the itinerary fits one of three layered schemes.

This article compares the 240-hour transit visa-free programme, the unilateral visa-free list, the regional entry schemes and the port-visa / APEC options, and gives a practical decision checklist. It complements — but does not duplicate — our companion pieces on work visas and the APEC Business Travel Card.

The 240-hour transit visa-free programme

The flagship convenience is the 240-hour (10-day) transit visa-free policy. A national of one of 55 designated countries, holding a valid international travel document and a connecting ticket with a confirmed date and seat to a third country or region, may enter visa-free through any of 65 open ports in 24 provinces and stay up to 10 days. During the stay, permitted activities include tourism, business, visiting and family reunion. Paid work, study and news reporting still require prior approval.

The scheme has been upgraded repeatedly: from 72 hours (2013), to 144 hours, to 240 hours, with the country list growing to 55 and ports to 65 by late 2025. For a business visitor transiting through China en route to a third country — say, Tokyo → Shanghai → Frankfurt — the 240-hour window is usually ample for meetings without any visa application.

Unilateral visa-free for 50 countries

Beyond transit, China applies a unilateral visa-free policy to 50 countries (as published by the National Immigration Administration on 17 February 2026). Nationals of these countries, travelling on an ordinary passport for business, tourism, family visits, exchanges or transit of no more than 30 days, may enter visa-free. The list spans Europe (35 countries, including France, Germany, Italy, the UK, Russia and the Nordics), Oceania (Australia, New Zealand), Asia (Japan, South Korea, Saudi Arabia, the Gulf states) and the Americas (Brazil, Argentina, Chile, Peru, Uruguay, Canada).

This is the single most useful instrument for short business development trips: a German or Brazilian executive can fly in, attend meetings, sign a term sheet and leave within 30 days with no consular step. It is unilateral — China grants it without reciprocity — and can be adjusted, so travellers should confirm the current list before booking.

Regional entry visa-free schemes

A family of *regional* schemes opens targeted corridors, useful when the trip blends business with leisure or centres on a specific zone:

  • Hainan: nationals of 59 countries may enter visa-free and stay up to 30 days.
  • Cruise tours: foreign tour groups of two or more may enter visa-free through 13 cruise ports along coastal provinces and Beijing, staying up to 15 days.
  • ASEAN tour groups: ASEAN nationals may enter visa-free as tour groups into Xishuangbanna (Yunnan) or Guilin (Guangxi), up to 6 days.
  • HK/Macau-organised foreign tour groups: foreign groups organised by HK or Macau travel agencies may enter the nine mainland cities of the Greater Bay Area plus Shantou, or Hainan, visa-free for up to 6 days.

For an investor combining site visits in the Greater Bay Area with a short holiday, the HK/Macau-group route is a practical, low-friction option.

Port visa and APEC Business Travel Card

When a trip does not fit the above — for example, a last-minute technical assignment, or a nationality outside the eligible lists — a port visa remains available. Qualifying foreign business visitors may, with an invitation letter from a domestic entity and supporting documents, apply for a visa on arrival at designated ports. Processing is fast and designed for genuine, time-sensitive commercial need.

The APEC Business Travel Card offers a multi-year, multi-economy shortcut for senior executives from APEC economies: it functions as a multiple-entry visa and enables expedited immigration lanes across member economies, materially cutting the administrative load of repeated travel. We cover it in detail separately.

Practical decision checklist

  1. Transiting to a third country? Use 240-hour transit visa-free (55 countries, 65 ports, 24 provinces).
  2. From one of the 50 unilateral countries, stay ≤30 days, no work/study? Enter visa-free directly.
  3. Trip centres on Hainan / a cruise / an ASEAN or HK-Macau group? Use the matching regional scheme.
  4. Eligible APEC economy executive with frequent travel? Hold an APEC card.
  5. None of the above, or paid work / study / reporting? Obtain the correct visa (port visa for urgent business; work/residence permit for employment).
  6. Always: confirm the current eligible-country list and port list before ticketing, carry the onward ticket, and never overstay.

Related reading

  • Work visas and residence permits for foreign employees in China.
  • The APEC Business Travel Card and port-visa routes for business travellers.
  • Regional visa-free entry schemes and the Greater Bay Area mobility picture.

2026年外国商务人员来华免签与口岸签证便利:过境免签、单方面免签与口岸签证对照

为何重要

便利人员往来已成为引资促商的一项明确工具。《利用外资固稳促优行动方案》(商务部、国家发展改革委、财政部,2026年第97号)明确将过境免签、离境退税与涉外支付等措施列为优化国际化营商环境的具体抓手。对于正盘算一周客户拜访、工厂巡查或董事会行程的外国高管而言,签证往往是第一道摩擦点。好消息是:只要行程契合三层便利方案之一,答案越来越可能是”你根本不需要签证”。

本文对比240小时过境免签、单方面免签清单、区域性入境免签,以及口岸签证与APEC选项,并给出实用的决策清单。它与本站点关于工作签证、APEC商务旅行卡的专文互为补充,但不重复。

240小时过境免签方案

最具标志性的便利是240小时(10天)过境免签。55个指定国家的公民,持有效国际旅行证件和前往第三国(地区)且日期、座位已确定的联程客票,可从24个省份的65个开放口岸免签入境,停留不超过10天。停留期间可从事旅游、商务、访问、探亲等活动;有偿工作、留学与新闻采访仍须事先批准。

该方案历经多次升级:从2013年的72小时,到144小时,再到240小时,适用国家增至55个、口岸增至65个(2025年底)。对于经中国中转前往第三国的商务访客——例如东京→上海→法兰克福——240小时窗口通常足以完成会议而无需任何签证申请。

对50国的单方面免签

在过境之外,中国对50个国家实施单方面免签(国家移民管理局2026年2月17日公布)。这些国家公民持普通护照,因经商、旅游观光、探亲访友、交流访问、过境事由来华、停留不超过30日的,可免签入境。清单覆盖欧洲(35国,含法国、德国、意大利、英国、俄罗斯及北欧国家)、大洋洲(澳大利亚、新西兰)、亚洲(日本、韩国、沙特及海湾国家)与美洲(巴西、阿根廷、智利、秘鲁、乌拉圭、加拿大)。

这是短期商务拓展行程最实用的工具:德国或巴西高管可以飞抵、参会、签署条款清单并在30天内离境,无需任何领事步骤。该政策是单边的(中国单方面给予、不要求对等),并可能调整,出行人应在订票前确认最新清单。

区域性入境免签方案

一族*区域性*方案打开了定向通道,适用于”商务+休闲”结合或围绕特定区域的行程:

  • 海南: 59国公民可免签入境,停留不超过30天。
  • 邮轮免签: 2人及以上外国旅游团可经13个邮轮口岸及北京市免签入境沿海省(区、市),停留不超过15天。
  • 东盟旅游团: 东盟国家旅游团可分别免签入境云南西双版纳或广西桂林,停留不超过6天。
  • 港澳组团: 经港澳旅行社组团的外国旅游团,可免签进入大湾区内地9市及汕头,或免签入境海南,停留不超过6天。

对于将大湾区实地考察与短途休假结合的投资者,港澳组团路线是务实、低摩擦的选择。

口岸签证与APEC商务旅行卡

当行程不符合上述情形——例如临时的技术派驻,或国籍不在适用清单内——口岸签证仍是可行路径。符合条件的外国商务人员,凭国内单位邀请函及证明材料,可在指定口岸落地申请签证。办理快捷,专为真实、时效敏感的商务需求设计。

APEC商务旅行卡为APEC经济体高管提供多年期、多经济体的通行捷径:兼具多次入境签证功能,并在成员经济体间启用快速通道,显著降低频繁出行的行政负担。本站点另有专文详述。

实用决策清单

  1. 经第三国中转? 用240小时过境免签(55国、65口岸、24省)。
  2. 来自50个单方面免签国、停留≤30天、无工作/留学? 直接免签入境。
  3. 行程围绕海南/邮轮/东盟或港澳组团? 用对应的区域性方案。
  4. 属APEC经济体、频繁出行的高管? 持有APEC卡。
  5. 以上均不符合,或有偿工作/留学/采访? 办理相应签证(紧急商务走口岸签证;就业办工作居留许可)。
  6. 始终: 订票前确认最新适用国家与口岸清单,携带后续行程客票,切勿逾期。

延伸阅读

  • 外籍员工在华的工作签证与居留许可。
  • APEC商务旅行卡与面向商务人员的口岸签证路径。
  • 区域性入境免签方案与大湾区的人员流动图景。

Sources

  • 国家移民管理局:单方面免签国家名单(2026年2月17日)— https://nia.gov.cn/n741440/n741577/c1731154/content.html
  • 国家移民管理局:中国240小时过境免签政策(在线咨询答复,含55国/65口岸)— https://www.nia.gov.cn/Enquiry/publish/preShowQuestion.jsp
  • 国家移民管理局官网(签证政策与出入境管理专栏)— https://www.nia.gov.cn

Fast-Track Entry for Foreign Business Visitors: China Port Visas and the APEC Business Travel Card

  • A port visa (口岸签证) lets a foreign business visitor obtain an M visa on arrival at a designated Chinese port, when invited by a verified local entity.
    口岸签证允许受邀的外籍商务人士在指定对外开放口岸落地办理M字签证。
  • The APEC Business Travel Card gives five-year, multi-entry access to 16 economies, with express clearance at dedicated lanes.
    APEC商务旅行卡提供五年多次、可入境16个经济体的待遇,并享专用通道快速通关。
  • A Chinese-venture’s mainland staff can hold the APEC card; foreign nationals apply to their own economy, not to China.
    中外合资、外商独资企业的中方人员可申办APEC卡;外籍人士向其所属经济体申请,不向中国申请。
  • Since April 2025, some cities run a special-invitation facility for frequent foreign business visitors, covering spouses and children.
    自2025年4月起,部分城市对外籍商务常客试行专项签证便利邀请函,惠及配偶与子女。
  • Port visas and the APEC card sit alongside the 240-hour transit and unilateral visa-free schemes as fast-track entry tools.
    口岸签证与APEC卡,与240小时过境免签、单方面免签共同构成快速入境工具箱。
  • Plan the document stack early: invitation letter, port-of-entry approval and, for the card, the foreign-affairs office filing.
    及早准备文件链:邀请函、入境口岸批准备案,持卡则经外事办公室申报。

Fast-Track Entry for Foreign Business Visitors: China Port Visas and the APEC Business Travel Card | 外籍商务人士快速入境:中国口岸签证与APEC商务旅行卡

The Fast-Track Toolkit

When a foreign business visitor needs to reach China quickly—for a signing, a board meeting, a factory audit or a tender—three fast-track tools sit alongside the familiar 240-hour transit and unilateral visa-free schemes: the port visa (口岸签证), the APEC Business Travel Card (ABTC), and the newer special-invitation facility for frequent business visitors. Each serves a different profile; together they shrink the time from “we need you in Shanghai” to “you are through immigration”.

Port Visas: a Visa on Arrival for Business

A port visa is issued by the exit-entry administration at a designated open port to a foreign national who holds an invitation from a verified Chinese entity and meets the statutory grounds—sudden commercial activity, tender participation, or other urgent, justified business need. The inviting entity applies in advance to the public-security exit-entry authority at the intended port of entry; once approved, the visitor obtains an M (business) visa on arrival without first visiting a Chinese embassy. Port visas are the right tool when lead time is too short for a consular application but the visit is genuine and documentable. They are not a substitute for long-stay work or residence permits.

The APEC Business Travel Card

The APEC Business Travel Card is a multilateral visa-facilitation arrangement among the 21 APEC economies. A Chinese cardholder receives five-year validity, multiple entry, and stays of at least 60 days per visit (60 or 90 days depending on the economy), plus express clearance at dedicated APEC lanes. China joined in 2002; mainland cardholders may enter 16 economies (the United States and Canada are transit members that do not approve external cardholders but offer expedited visa and clearance conveniences). The card is for business travel only—not tourism, family visits or medical trips.

Who Can Hold the Card

Under the scheme, eligible Chinese applicants include government officials handling APEC affairs, central and local state-owned enterprise personnel, private-enterprise personnel, and personnel of Chinese-foreign equity joint ventures, wholly foreign-owned enterprises and Hong Kong/Macao/Taiwan-invested enterprises. The application runs a three-tier review: the enterprise preliminarily reviews, the local foreign-affairs office reviews, and the Department of Consular Affairs of the Ministry of Foreign Affairs gives final approval. A foreign national cannot apply for the card in China—they apply to their own economy’s authority. From 2023, a virtual card with equal legal effect is accepted for foreign nationals entering China.

The 2025 Special-Invitation Facility

Since April 2025, several cities have trialled a special visa-facilitation invitation letter for foreign business visitors with frequent, well-recorded travel to China. Invited visitors—often senior executives and technical staff of foreign-invested enterprises—obtain a single visa procedure that yields a five-year, multiple-entry visa with stays up to 180 days, and the benefit extends to spouses and minor children. In one city’s account, the facility sat alongside the 240-hour transit, the 30-day unilateral visa-free and the 30-day business visa as a fifth, longer-horizon option for trusted business travellers.

How the Tools Compare

ToolBest forValidity / stayWho applies
Port visaUrgent, short, documentable visitM visa on arrivalInvited visitor, via host entity
APEC cardRecurring Asia-Pacific travel5 years, multi-entry, 60–90 daysChinese-venture mainland staff
Special invitationFrequent trusted visitors5 years, up to 180 days, familyHost city foreign-affairs office
240-hour transitBack-to-back regional trips240 hours, no visaEligible transit nationalities
Unilateral visa-freeShort leisure/business stays30 days, no visaListed countries

Practical Steps for a Foreign-Invested Enterprise

  1. Keep an invitation template ready: entity details, visitor profile, purpose, itinerary and port of entry.
  2. For urgent arrivals, pre-file the port visa with the exit-entry authority at the chosen port; do not rely on walk-up issuance.
  3. Enrol frequent mainland travellers for the APEC card through the local foreign-affairs office; budget two to three months for multi-economy approval.
  4. Ask the host city about the special-invitation facility if you have recurring senior visitors.
  5. Track stay limits—port visas and transit are short; for work or residence, use the proper permit, not a business visa.
  6. Centralise the record—keep invitation letters, port approvals, card filings and entry stamps in one file so the next application is repeatable and auditable.

Related Reading

See our 240-hour visa-free transit guide (No. 79), regional visa-free schemes in 2026 (No. 173) and unilateral visa-free policy (No. 186).


外籍商务人士快速入境:中国口岸签证与APEC商务旅行卡

快速入境工具箱

当外籍商务人士需紧急来华——签约、董事会、工厂审核或投标——除熟知的240小时过境免签与单方面免签外,还有三件快速工具:口岸签证、APEC商务旅行卡与较新的外籍商务常客专项签证便利邀请函。三者适配不同人群,共同把”我们需要你到上海”到”你已过边检”的时间大幅压缩。

口岸签证:落地即办的商务签证

口岸签证由指定对外开放口岸的公安出入境管理机关,向持有经核实的中国境内单位邀请、且符合法定情形——临时商务活动、参与投标或其他紧急正当商务需求——的外国人签发。邀请单位事先向拟入境口岸的公安出入境机关申请;获批后,访客抵港即可办理M字(商务)签证,无需先赴中国使馆。当时间不足以走领事申请、但访问真实且有据可查时,口岸签证是最合适的工具。它不能替代长期的工作或居留许可。

APEC商务旅行卡

APEC商务旅行卡是21个APEC经济体间的多边签证便利化安排。中国持卡人享有五年有效、多次入境、每次停留至少60天(按经济体为60或90天),并在APEC专用通道快速通关。中国于2002年加入;内地持卡人可入境16个经济体(美国、加拿大为过渡成员,不审批外部持卡人,但提供签证与通关便利)。该卡仅用于商务旅行,不适用于旅游、探亲或就医。

谁能持卡

根据制度,符合条件的中国申请人包括:从事APEC事务的政府官员,中央及地方国有企业人员,民营企业人员,以及中外合资、外商独资和港澳台资企业的中方人员。申请实行三级审批:企业初审、地方外办复审、外交部领事司终审。外籍人士不能在中国申请该卡——须向其所属经济体主管部门申请。2023年起,具有同等效力的虚拟卡被接受用于外籍人士入境。

2025年专项签证便利邀请函

自2025年4月起,多个城市对外籍商务常客试行专项签证便利邀请函。受邀者多为外资企业的外籍高管与技术骨干,一次签证手续即可获得五年多次、单次最长180天、并惠及配偶与未成年子女的签证。据某市表述,该便利与240小时过境、30天单方面免签、30天商务签证并列,成为面向可信商务旅客的第五种、更长效选项。

工具对比

工具最适用有效期/停留由谁申请
口岸签证紧急、短期、有凭证的访问落地M签证受邀访客,经邀请单位
APEC卡频繁的亚太差旅5年、多次、60—90天外资企业中方人员
专项邀请频繁可信访客5年、最长180天、含家属属地外事办公室
240小时过境接连的区域行程240小时、免签符合条件过境国籍
单方面免签短期商务/休闲30天、免签清单内国家

外资企业的实操步骤

  1. 备好邀请函模板:单位信息、访客画像、目的、行程与入境口岸。
  2. 紧急抵达时,预先在选定口岸的出入境机关申报口岸签证;不要依赖现场即办。
  3. 为频繁出行的境内人员申办APEC卡,经属地外事办公室;预留二至三个月多经济体审批周期。
  4. 如有反复到访的高管,向属地城市咨询专项邀请便利。
  5. 盯住停留上限——口岸签证与过境均较短;工作或居留须用相应许可,而非商务签证。
  6. 集中归档——将邀请函、口岸批准备案、持卡申报与入境验讫章归入同一档案,使下一次申请可复用、可审计。

延伸阅读

可参阅本站240小时过境免签指南(编号79)、2026年区域性免签政策(编号173)与单方面免签政策(编号186)。

Sources

China’s Unilateral Visa-Free Policy: A Practical Guide for Foreign Business Travellers (2026)

  • China now grants unilateral visa-free entry to ordinary passport holders of 50 countries, valid nationwide for stays up to 30 days.
    中国目前对 50 个国家的普通护照持有人实施单方面免签,可在全国范围停留不超过 30 天。
  • The policy was extended on 3 November 2025 to 31 December 2026, and Sweden was added as the latest European entrant from 10 November 2025.
    该政策于 2025 年 11 月 3 日延期至 2026 年 12 月 31 日,并自 2025 年 11 月 10 日起将瑞典纳入免签范围。
  • No visa, no connecting ticket, and no pre-arranged invitation are required — but paid employment is strictly prohibited under the waiver.
    免签入境无需签证、无需联程客票、也无需预先邀请函,但严禁以该政策从事有偿工作。
  • The 30-day clock starts on the calendar day after entry, and overstayers must apply for a stay permit rather than a simple extension.
    30 天停留期自入境次日零时起算,超期者须申请停留证件而非简单续签。
  • Unilateral visa-free entry is nationwide and individual-based, unlike the 240-hour transit waiver (third-country onward ticket, limited ports) and regional entry waivers (Hainan, cruise, ASEAN groups).
    单方面免签面向个人、全国通行,与 240 小时过境免签(需赴第三国联程票、限定口岸)及区域性入境免签(海南、邮轮、东盟旅游团)明显不同。
  • Foreign business travellers can use it for short trips — meetings, site visits, trade fairs, and partner exchanges — without a formal work visa, as long as they do not take up local employment.
    外籍商务人士可用它开展短期差旅——会议、实地考察、参展、伙伴交流——无需正式工作签证,前提是不在当地受雇务工。

China’s Unilateral Visa-Free Policy: A Practical Guide for Foreign Business Travellers (2026) | 中国单方面免签政策:外籍商务差旅实操指引(2026)

Overview

Since late 2023, China has rolled out one of the most significant liberalisations of its short-stay entry regime in decades: a unilateral visa waiver under which ordinary passport holders of a growing list of countries may enter China without a visa for business, tourism, family visits, exchange, or transit, for stays of no more than 30 days. Unlike reciprocal treaties, this waiver is granted by China alone.

By March 2026, Foreign Minister Wang Yi confirmed unilateral visa-free arrangements for 50 countries and full mutual visa-free agreements with 29 countries, with visa-free entries at 73% of all foreign arrivals. This article focuses on the unilateral stream — its country coverage, the 2024–2026 expansion rhythm, and the practical entry rules.

The waiver is deliberately simple. It removes the single biggest friction point for short visits — obtaining a Chinese visa in advance — and applies nationwide, not just to specific provinces or ports. For foreign-invested enterprises, chambers of commerce, and individual professionals, it has become the default channel for short business trips.

Which countries are covered

The 50-country list is the result of incremental additions between November 2023 and February 2026, grouped by region below (per the February 2026 consular FAQ and the November 2025 extension notice).

RegionCountries (ordinary passport holders)
Europe (32)France, Germany, Italy, Netherlands, Spain, Switzerland, Ireland, Hungary, Austria, Belgium, Luxembourg, Poland, Portugal, Greece, Cyprus, Slovenia, Slovakia, Norway, Finland, Denmark, Iceland, Andorra, Monaco, Liechtenstein, Bulgaria, Romania, Croatia, Montenegro, North Macedonia, Malta, Estonia, Latvia
Asia (7)Brunei, Republic of Korea, Japan, Saudi Arabia, Oman, Kuwait, Bahrain
Oceania (2)Australia, New Zealand
Americas (5)Brazil, Argentina, Chile, Peru, Uruguay
Added later (4)Russia (Sep 2025), Sweden (Nov 2025), Canada (Feb 2026), United Kingdom (Feb 2026)

Validity notes for trip planning:

  • Brunei — open-ended, no expiry set.
  • Russia — per the February 2026 FAQ, currently runs to 31 December 2027.
  • The other 48 countries — extended to 24:00 on 31 December 2026.
  • Sweden — from 10 November 2025 to 31 December 2026.
  • Canada and the United Kingdom — from 17 February 2026 to 31 December 2026.

Because the list has shifted several times, re-confirm against the latest consular notice before booking.

The 2024–2026 expansion and extension timeline

The policy expanded in waves, each later bundled into a single extension. Key milestones:

  • Dec 2023 – Nov 2024: Pilot waiver for France, Germany, Italy, Netherlands, Spain, and Malaysia (15-day stay).
  • Mid-2024: Australia and New Zealand added, then a bloc of Central and Eastern European states and the Republic of Korea.
  • Late 2024: Japan and South American states Brazil, Argentina, Chile, Peru, and Uruguay added.
  • 9 June 2025: Saudi Arabia, Oman, Kuwait, and Bahrain added (initially a one-year trial).
  • 15 September 2025: Russia added.
  • 3 November 2025: The Ministry of Foreign Affairs announced the extension of the 45-country waiver to 31 December 2026 and added Sweden (effective 10 November 2025).
  • 17 February 2026: Canada and the United Kingdom added, also to 31 December 2026.

Frequent, often annual, extensions plus steady additions define the unilateral stream. Policymakers have signalled intent to keep optimising it, so further extensions beyond 2026 are widely expected.

Practical entry rules

The waiver is governed by the consular FAQ and border-inspection practice. The essentials:

  1. No visa required. Eligible nationals present a valid ordinary passport at an open port.
  2. No connecting ticket required. Unlike the transit waiver, no onward ticket to a third country is needed; entry and exit may be from any country or region.
  3. Purpose of stay. Business, tourism, family/friend visits, exchange, and transit are covered, as are study tours, conferences, exhibitions, and sports competitions under 30 days.
  4. No employment. The waiver does not apply to work, study, journalism, or similar purposes. Paid local employment is prohibited; use a proper work or Z-visa pathway.
  5. Passport validity. An ordinary passport valid for at least the intended stay is needed. Travel, temporary, or emergency documents are not accepted.
  6. Any mode and any port. Entry by air, sea, or road through any open port is allowed (private vehicles need ordinary transport-entry formalities).
  7. Stay calculation. The 30 days run from the calendar day after entry (自入境次日起算).
  8. Overstay handling. For proper reasons beyond 30 days, apply for a stay permit (停留证件); a simple visa-free “extension” does not exist.
  9. Supporting documents. Border inspection may verify purpose; carry an invitation letter, bookings, or similar proof. Minors follow the same rules.

For business travellers, a routine market visit, supplier meeting, or trade-fair trip is frictionless within 30 days and without employment.

How it differs from transit and regional waivers

China operates three distinct short-stay entry channels:

  • Unilateral visa-free (this article): nationwide, individual-based, up to 30 days, no onward ticket, no visa. Covers the 50 named countries.
  • 240-hour transit waiver (covered in article 79): confirmed onward ticket to a third country/region, designated ports in 24 provinces, stay within defined areas up to 10 days. Open to ~55 countries.
  • Regional entry waivers (covered in article 173): geographically confined — 30-day Hainan entry for 59 countries, cruise groups through 13 ports, ASEAN groups in Yunnan and Guangxi. Group or area limits apply.

In short: the unilateral waiver is the most flexible for an individual business trip; the transit waiver is for genuine onward travel; the regional waivers are for destination-specific tourism.

What foreign businesses should do

For FDI-related travel, the unilateral waiver lowers the cost of doing business in China. Recommended steps:

  1. Map eligible nationalities. If your headquarters, suppliers, or clients are in the 50 countries, short trips need no visa lead time.
  2. Keep trips under 30 days and non-employment. Use the waiver for meetings, inspections, due diligence, and exhibitions; for assignments or on-site work, use a work or business (M) visa.
  3. Carry purpose evidence. A Chinese invitation letter (邀请函) and bookings smooth border inspection and later stay-permit applications.
  4. Plan around expiry dates. Waivers lapse on 31 December 2026 (Russia to 2027). Watch for the next extension round before year-end trips.
  5. Combine with the transit waiver. Travellers from non-listed countries (e.g., the United States) can still use the 240-hour transit waiver for genuine onward journeys.
  6. Brief relocating staff separately. The waiver is not a route to residency; long-term presence needs the standard work- and residence-permit process.

Related reading

  • 240-hour visa-free transit (article 79) — the onward-ticket, port-limited channel.
  • Regional entry waivers (article 173) — Hainan, cruise, and ASEAN group entry.
  • Ministry of Foreign Affairs consular FAQ and mutual visa-free treaty list for the latest country updates.

中国单方面免签政策:外籍商务差旅实操指引(2026)/ China’s Unilateral Visa-Free Policy: A Practical Guide for Foreign Business Travellers (2026)

概述

自 2023 年底起,中国推出了数十年来力度最大的短期入境便利化举措之一——单方面免签政策:符合清单的国家,其普通护照持有人来华经商、旅游观光、探亲访友、交流访问、过境,停留不超过 30 天的,可免办签证入境。与对等(互免)签证协定不同,这一免签由中国单方给予,伙伴国无须对中国护照持有人给予同等待遇。对企业而言,这意味着总部外派、客户拜访、供应商审核等高频短差,不再被签证周期”卡脖子”,决策与成行之间的时滞大幅压缩。

截至 2026 年 3 月,外交部长王毅确认,中国已对 50 个国家实施单方面免签,并与 29 个国家实现全面互免签证,前一年免签入境的外籍人士占比高达 73%。在稳外资、扩开放的背景下,这条通道对外国投资者意义尤为直接:它把”想来就能来”的门槛降到最低。本文聚焦”单方面免签”这一条线——覆盖国家、2024–2026 年的扩容与延期节奏、入境实操规则,以及它与本站点另文介绍的 240 小时过境免签和区域性入境免签的区别。

单方面免签的设计刻意保持简单:它消除了短期访问最大的摩擦点——提前办理中国签证,而且适用全国,而不限于特定省份或口岸。对外商投资企业、商会以及个人专业人士而言,它已成为短期差旅的默认通道。与互免协定不同,这一便利由中国单方给予,伙伴国无须对中国护照持有人对等开放,因此扩容节奏完全由中国自主决定,这也解释了为何名单能在两年内迅速拉长。值得注意的是,单方面免签与互免协定并行不悖:前者针对 50 国、后者覆盖 29 国,二者共同构成中国”免签朋友圈”的双支柱,外籍人士来华短期停留的便利度因此大幅提升。

覆盖哪些国家

这 50 国名单是 2023 年 11 月至 2026 年 2 月逐步扩容的结果,呈现出”欧洲为主、亚太与美洲跟进、海湾与北美收尾”的清晰轨迹。下表按地区分组(依据 2026 年 2 月领事常见问题解答及 2025 年 11 月延期通知):

地区国家(普通护照持有人)
欧洲(32 国)法国、德国、意大利、荷兰、西班牙、瑞士、爱尔兰、匈牙利、奥地利、比利时、卢森堡、波兰、葡萄牙、希腊、塞浦路斯、斯洛文尼亚、斯洛伐克、挪威、芬兰、丹麦、冰岛、安道尔、摩纳哥、列支敦士登、保加利亚、罗马尼亚、克罗地亚、黑山、北马其顿、马耳他、爱沙尼亚、拉脱维亚
亚洲(7 国)文莱、韩国、日本、沙特、阿曼、科威特、巴林
大洋洲(2 国)澳大利亚、新西兰
美洲(5 国)巴西、阿根廷、智利、秘鲁、乌拉圭
后续新增(4 国)俄罗斯(2025 年 9 月)、瑞典(2025 年 11 月)、加拿大(2026 年 2 月)、英国(2026 年 2 月)

出行规划需注意以下有效期要点:

  • 文莱——未设截止日期,免签长期有效,是清单中唯一无明确到期日的国家。
  • 俄罗斯——试行免签自 2025 年 9 月 15 日至 2026 年 9 月 14 日,但 2025 年 11 月的延期将一般截止日推至 2026 年 12 月 31 日;据 2026 年 2 月领事解答,俄罗斯安排目前施行至 2027 年 12 月 31 日,是有效期最长者。
  • 其余 48 国——免签均延期至 2026 年 12 月 31 日 24 时。
  • 瑞典——自 2025 年 11 月 10 日起覆盖至 2026 年 12 月 31 日,是欧洲名单中的最新成员。
  • 加拿大、英国——自 2026 年 2 月 17 日起覆盖至 2026 年 12 月 31 日,是北美两大经济体加入的标志性节点。

由于名单多次调整,旅行者应在订票前务必对照最新领事通知再次核实,因为各试用期和截止日会随每次延期而变动。建议把”以出发当日官方清单为准”作为内部差旅政策的硬性提醒。

2024–2026 年扩容与延期节奏

该政策并非一次性成型,而是分批扩容,每批随后又被统一延期。关键节点如下:

  • 2023 年 12 月 1 日 – 2024 年 11 月 30 日:对法国、德国、意大利、荷兰、西班牙、马来西亚试行免签(停留 15 天),迈开单方面开放的第一步。
  • 2024 年中:新增澳大利亚、新西兰;随后加入一批中东欧国家(如匈牙利、奥地利、比利时、瑞士、波兰、葡萄牙、希腊等)及韩国,欧洲”朋友圈”迅速铺开。
  • 2024 年底:新增日本,以及南美的巴西、阿根廷、智利、秘鲁、乌拉圭,并加入更多欧洲国家,名单首次突破四十国量级。
  • 2025 年 6 月 9 日:新增沙特、阿曼、科威特、巴林,海湾阿拉伯国家首次整批进入免签清单。
  • 2025 年 9 月 15 日:新增俄罗斯,地缘邻近的大体量客源市场被纳入。
  • 2025 年 11 月 3 日:外交部宣布将 45 国免签延期至 2026 年 12 月 31 日,并新增瑞典(自 2025 年 11 月 10 日起),把北欧主要经济体补齐。
  • 2026 年 2 月 17 日:新增加拿大、英国,传统英语国家两大经济体入场,名单最终达到 50 国。

这种”频繁、往往按年”的延期叠加持续扩员,是单方面免签最鲜明的特征。政策制定者已释放出继续优化的信号,外界普遍预期 2026 年之后还会进一步延期,企业可将其作为中期可依赖的常态通道来规划。

入境实操规则

免签政策由领事常见问题解答及边检实践规范,要点如下:

  1. 无需签证。 符合条件者只需在对外开放口岸出示有效普通护照即可,无需提前向使领馆送签、缴费、等待制证。
  2. 无需联程客票。 与过境免签不同,您不需要赴第三国的联程机票,可从任何国家或地区出入境,往返行程自由安排。
  3. 入境目的。 经商、旅游、探亲访友、交流、过境均涵盖;不超过 30 天的研学、参会、参展、体育竞赛同样适用,覆盖面较广。
  4. 不得就业。 免签不适用于工作、学习、新闻采访等目的。禁止在当地从事有偿工作,须走正规的工作签证(Z 字签证)路径;即便短期项目支持,也建议先确认是否落入”就业”范畴。
  5. 护照有效性。 须持有效期至少覆盖拟停留期的普通护照。旅行证、临时或紧急护照不能用于免签入境。
  6. 任何交通方式、任何口岸。 经航空、海路或陆路从任一对外开放口岸入境均可(私家车入境须按规办理交通工具入出境手续)。
  7. 停留期计算。 30 天自入境次日零时起算,满 30 个自然日;例如 1 日入境,停留期至当月 31 日届满。
  8. 超期处理。 因正当理由需超过 30 天的,应向公安出入境管理部门申请停留证件;不存在”免签直接续期”一说,勿心存侥幸逾期。
  9. 佐证材料。 边检可能核实入境目的。请携带与所申报目的相符的邀请函、机票/酒店预订等证明;未成年人与成年人规则一致。

对商务旅客而言,常规的市场走访、供应商会议、参展等差旅因此变得顺畅——只要停留不超过 30 天且不越界就业,几乎可以”说走就走”。

与过境免签、区域性免签的区别

中国有三条性质不同的短期入境通道,需厘清:

  • 单方面免签(本文):全国通行、面向个人、最长 30 天、无需联程票、无需签证。覆盖前述 50 国,是三者中自由度最高的”个人通道”。
  • 240 小时过境免签(79 号文):须持赴第三国/地区的确定联程客票,从 24 个省份指定口岸入境,在规定区域停留不超过 10 天。面向约 55 国,本质是”中转”便利。
  • 区域性入境免签(173 号文):受地域限制——59 国入境海南 30 天、13 个邮轮口岸的旅游团入境、东盟旅游团赴云南(西双版纳)与广西(桂林)。多有限团或限区要求,属”目的地”便利。

简言之:单方面免签对个人商务差旅最灵活;过境免签适用于真实的中转行程;区域性免签适用于特定目的地旅游。三者各有适用面,企业可按行程性质择优选用。

需要特别提示的是,这三条通道并非互相排斥:同一位旅客完全可能在一次行程中组合使用。例如,一位不在 50 国清单内的美国商务人士,可先以 240 小时过境免签入境参会,若后续还需以个人身份旅游,则可另行规划。理解各自边界,才能把政策红利用足而不越线。

外籍商务人士应如何运用

就外资相关差旅而言,单方面免签显著降低了在华营商成本。建议做法:

  1. 梳理组织内符合资格国籍。 若总部、供应商或客户位于 50 国之中,短期行程无需签证办理周期,可把”免签国公民”标注在差旅系统中,减少行政摩擦。
  2. 行程控制在 30 天内且非就业。 用免签开展会议、考察、尽职调查、参展;若涉及派驻、培训或现场作业,请使用相应的工作签证或商务(M)签证,避免以免签”打擦边球”。
  3. 携带目的佐证。 中文邀请函及预订记录可顺畅边检,也便于后续申请停留证件;建议由境内实体统一出具邀请函模板。
  4. 关注有效期节点。 当前免签于 2026 年 12 月 31 日到期(俄罗斯至 2027 年)。年末出行前留意下一轮延期公告,必要时预留签证办理缓冲。
  5. 必要时与过境免签搭配。 非清单国家旅客(如不在单方面免签名单内的美国)仍可就真实中转行程使用 240 小时过境免签,二者互补而非互斥。
  6. 长期派驻另作安排。 免签不是居留或就业通道;长期停留须走标准的工作许可与居留许可流程,提前规划以避免身份真空。

相关阅读

  • 240 小时过境免签(79 号文)——需联程票、限口岸的通道,适合真实中转行程。
  • 区域性入境免签(173 号文)——海南、邮轮、东盟旅游团入境,适合目的地型旅游。
  • 外交部领事常见问题解答及互免签证协定一览表,获取最新国家更新与互免范围。

如需判断某位外籍员工适用哪条通道,可先按其国籍对照本文 50 国清单;不在清单内者,再评估是否满足 240 小时过境免签或区域性免签条件。三层通道叠加,已能覆盖绝大多数短期来华场景。

Sources

Foreigner Work and Residence Permit “One-Stop” Reforms Across China: Jinan, Xiamen, Hainan and the 2026 Joint-Processing Wave

  • On 12 August 2026 Jinan High-tech Zone opened the city’s first joint window for foreigner work permits and residence permits, completing the entire process in under ten minutes for its first applicant — a shift from multi-window, multi-visit processing to one-stop parallel approval.
    2026 年 8 月 12 日,济南高新区启用全市首个”外国人来华工作许可、居留许可联办窗口”,首位申请者不到十分钟完成全部手续——从”多窗跑多次”变为”一次提交、并联审批、一站式办结”。
  • The joint model integrates the work permit, work-type residence permit, social insurance registration and professional title review in one service zone, compressing processing from 35 working days to about 10 working days — an efficiency gain of over 70%.
    联办模式把工作许可、工作类居留证件、社保登记与职称评审整合到同一服务专区,办理时限从 35 个工作日压缩至约 10 个工作日,效率提升超 70%。
  • Xiamen has cut application materials from 42 to 21 items (a 50% reduction) for foreigner work-related matters, and Fujian’s NDRC has promoted the practice as a province-wide best-practice case for improving the business environment.
    厦门将外国人工作相关事项申请材料从 42 份精简至 21 份(精简率 50%),福建省发改委将其作为优化营商环境典型经验在全省推广。
  • Hainan has launched a “Work in China” one-stop solution on the provincial international services website, consolidating nine services including work permits, residence permits, social insurance registration and overseas professional qualification recognition into a single online entryway.
    海南在省级国际服务平台上线”Work in China”一站式解决方案,把外国人来华工作许可、工作类居留许可、社保登记、境外职业资格认可等 9 项服务整合进单一在线入口。
  • For employers, the practical effect is a faster, more predictable hiring timeline for foreign staff, lower compliance workload and clearer points of contact — but work-permit eligibility (A/B/C classification) and the underlying application requirements remain unchanged.
    对外资雇主,实际效果是招聘外籍员工的时间线更快、更可预期,合规工作量与对接点更清晰——但工作许可 A/B/C 分类与底层申请条件未变。

Foreigner Work and Residence Permit “One-Stop” Reforms Across China: Jinan, Xiamen, Hainan and the 2026 Joint-Processing Wave | 外国人来华工作与居留许可”一件事”改革:济南、厦门、海南与 2026 年联办浪潮

The joint window opens in Jinan

On 12 August 2026 the Jinan High-tech Zone administrative service centre opened the city’s first “foreigner work permit and residence permit joint window”. The first applicant, a Russian national completing a residence-permit renewal for his role as a sales manager at a Jinan import-export company, finished the entire process in under ten minutes. Under the previous arrangement, foreign staff and their employers shuttled between different windows — the work permit with the science and technology department, the residence permit with the public security entry-exit authority, social insurance elsewhere — with the whole sequence reportedly taking around 35 working days. The joint window compresses the process to about ten working days through parallel approval, an efficiency gain of more than 70%. The high-tech zone’s service area also integrates social insurance registration and information changes, professional title review coordination and, through third-party resources, notarisation services and talent-policy interpretation — what the zone describes as a complete “foreign-related HR administration package” for employers.

The Xiamen template and the Fujian promotion

Xiamen has gone furthest in quantifying the simplification. The city’s human resources and social security bureau, together with the public security bureau and the tax bureau, restructured four matters involved in foreigner work — work-permit issuance, change and extension; work-type residence permit issuance; and tax-registration-related items — from a serial, three-department process into an integrated “one window, parallel approval” model. The result: application materials were cut from 42 to 21 items, a 50% reduction. Fujian’s Development and Reform Commission has promoted the Xiamen practice as a province-wide best-practice case for business-environment improvement (the second batch of 2026). For employers, the Xiamen case demonstrates that the joint-processing reform is not a single-city experiment but a template being propagated at provincial level.

The Hainan “Work in China” platform

Hainan has taken the reform online. The province launched a “Work in China” one-stop solution on the Hainan International Service Website (wssp.hainan.gov.cn) and the Haiyiban platform, consolidating nine services — including foreigner work permits, work-type residence permits, employee social insurance registrations and overseas professional qualification recognition — into a single online entryway with automated data sharing. Applicants and companies log in with individual or corporate accounts under the “Efficient One-Stop Services” section, complete forms, submit applications and track progress in real time. The online model matters for employers because it removes the need to know which department handles which step: one platform, one account, one application record.

The wider pattern

The Jinan, Xiamen and Hainan cases sit within a broader national pattern. Songshan Lake in Dongguan has run a joint work-permit and residence-permit window since July 2026 through the city’s immigration services sub-centre; Foshan publishes a “foreigner work in China, one thing” guide covering work permits, residence documents, social security cards, and professional title review; and multiple provinces are converting the “one thing” reform from a convenience into a standard for foreign-related government services. The reform is administrative, not legal: the underlying regime remains the work permit classification system (Category A high-level talent, Category B professionals, Category C ordinary workers), the invitation-letter requirement and the point-based evaluation, and the validity periods of work permits and residence permits are unchanged. What has changed is the procedural interface.

Why the reform matters for foreign employers

For a foreign-invested company hiring expatriate staff, the practical gains are substantial. First, hiring timelines shrink: a joint process of about ten working days versus a serial process of over a month materially shortens the gap between offer and start date. Second, administrative burden falls: one set of documents, one submission, one point of contact, instead of multiple departments and repeated filings. Third, predictability improves: with clearly defined windows and online tracking, employers can plan onboarding around a reliable calendar. Fourth, the extension and renewal path is smoother: renewal — the case type of Jinan’s first applicant — benefits most from the joint model because the same documents are needed by both authorities. Fifth, integration with adjacent services (social insurance, tax registration, professional title review, notarisation) reduces the number of separate visits an employee must make in the first months of employment.

Practical guidance for employers

First, before recruiting, confirm the job’s work-permit category (A/B/C) and that the foreign candidate meets the salary, education and experience thresholds, since the joint window speeds up processing, not eligibility. Second, in the four cities and provinces with joint windows, prepare a single document package aligned to the window’s checklist; in other locations, continue to prepare the department-by-department packages but watch for local “one thing” reforms. Third, use the online platforms where available (Hainan’s “Work in China”, local government service networks) and keep employer account details ready. Fourth, plan social insurance and tax registration at the same time as the permit applications, since the integrated service zones now handle them in parallel. Fifth, monitor provincial business-environment case lists — the Xiamen case shows that local reform innovations are being catalogued and propagated, and the next joint-window city may be the one you operate in.

Outlook

The 2026 joint-processing wave is converting China’s foreigner work and residence administration from a multi-department burden into a streamlined, increasingly online process. The underlying eligibility rules are unchanged, but the procedural interface — one window, parallel approval, reduced materials, online tracking — is being normalised city by city and province by province. For foreign employers and their HR teams, the practical message is to audit which joint services are available in each operating location and to build the hiring calendar around them, because the direction of reform is unambiguous: faster, simpler and more predictable.

Sources


外国人来华工作与居留许可”一件事”改革:济南、厦门、海南与 2026 年联办浪潮

联办窗口在济南启用

2026 年 8 月 12 日,济南高新区政务服务中心启用全市首个”外国人来华工作许可、居留许可联办窗口”。首位申请者——一名在济南进出口企业任销售经理、办理居留许可延期的俄罗斯青年——不到十分钟完成全部手续。此前,外籍员工与雇主需在不同窗口之间奔波:工作许可找科技部门、居留许可找公安出入境、社保又另寻他处,全程据称约需 35 个工作日。联办窗口通过并联审批把时限压缩至约 10 个工作日,效率提升超 70%。高新区服务专区还整合社保登记及信息变更、职称评定对接,并经第三方资源提供涉外公证与人才政策解读——用园区的话说,为雇主提供一整套”涉外 HR 政务集成方案”。

厦门模板与福建推广

厦门在量化简化方面走得最远。市人社局牵头,联合市公安局、市税务局,把外国人工作涉及的 4 个事项——工作许可签发、变更、延期,工作类居留证件签发,税务登记关联事项——从”串联跑三部门”改造为”一窗受理、并联审批”集成模式。结果:申请材料从 42 份精简至 21 份,精简率 50%。福建省发改委已把厦门做法作为 2026 年第二批优化营商环境典型经验在全省推广。对雇主,厦门案例表明联办改革不是单城试验,而是省级推广的模板。

海南”Work in China”平台

海南把改革搬上线上。该省在国际服务网站(wssp.hainan.gov.cn)与”海易办”平台上线”Work in China”一站式解决方案,把外国人来华工作许可、工作类居留许可、员工社保登记、境外职业资格认可等 9 项服务整合进单一在线入口,自动数据共享。申请人与企业以个人或企业账户登录”高效办成一件事”专栏,在线填表、提交、实时跟踪进度。在线模式对雇主的意义在于不必再知道哪一步归哪个部门:一个平台、一个账户、一份申请记录。

更大范围的模式

济南、厦门、海南案例属于更广的全国模式。东莞松山湖自 2026 年 7 月起依托东莞移民事务服务中心松山湖分中心实现工作许可与居留许可”一窗办理、并联审批”;佛山发布”外国人来华工作一件事”办事指引,覆盖工作许可、居留证件、社保卡与职称评审;多省正把”一件事”改革从便利升级为涉外政务标准。改革是行政性的,而非法律性的:底层制度未变——工作许可 A(高层次人才)、B(专业人才)、C(普通人员)分类、邀请函要求与积分评估、工作许可与居留许可有效期均不变。变化的是程序界面。

改革对外资雇主的意义

对招聘外籍员工的外资企业,实际收益可观。其一,招聘周期缩短:约 10 个工作日的联办流程对比一个多月的串联流程,实质缩短从录用通知到入职的空档。其二,行政负担下降:一套材料、一次提交、一个对接点,取代多部门与重复申报。其三,可预期性提高:窗口与在线跟踪明确,雇主可围绕可靠日历规划入职。其四,延期与续办更顺:续办——济南首位申请者的案件类型——最受益于联办,因为两部门需要同一套文件。其五,与相邻服务(社保、税务登记、职称评审、公证)的整合减少员工入职头几个月须单独跑的次数。

雇主实操指引

其一,招聘前确认岗位工作许可类别(A/B/C)与候选人薪酬、学历、经验门槛——联办提速的是办理,不是资格。其二,在已设联办窗口的四城/省份,按窗口清单准备单一文件包;其他地区继续按部门分套准备,但留意本地”一件事”改革。其三,可用处善用在线平台(海南”Work in China”、各地政务网),备好雇主账户。其四,在提交许可申请的同时规划社保与税务登记——集成服务专区现已并联办理。其五,跟踪省级营商环境案例清单——厦门案例表明地方创新正被建档推广,下一个联办窗口城市可能正是你运营之地。

展望

2026 年联办浪潮正把中国外国人工作与居留管理从多部门负担转化为精简、日益在线的流程。底层资格规则未变,但程序界面——一窗、并联、减材料、在线跟踪——正逐城逐省常态化。对外国雇主与 HR 团队,实务信息是审计各运营地可用联办服务,并围绕它们构建招聘日历——改革方向无可置疑:更快、更简、更可预期。

Sources